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Abstract  
Thymic epithelial tumors (TETs) are rare neoplasms classified in thymoma 
and thymic carcinoma. According to the 2004 WHO classification, thymomas are 
further subdivided into five subcategories (A, AB, B1, B2, B3), depending on cancer 
cell shape, degree of atypia and number of intratumoral thymocytes. Surgical 
resection is recommended for localized tumors, but systemic therapy is the choice for 
metastatic and not resectable neoplasms.  Usually, TETs respond to chemotherapeutic 
drugs but their effect lasts only for a limited time, thus, new targeted-molecules are 
currently under evaluation. However, the efficacy of biologic therapies in TET is 
scant, to date. The main limitation is the lack of a robust rationale to target specific 
molecules, mainly because the aberrations driving TET growth are obscure.  
The aim of this project is to clarify the molecular aberration driving the TET 
growth.  
Firstly, the frequency of aberrations described in TET case-reports has been 
evaluated. The presence of BRD4-NUT fusion gene was tested in 148 TETs, but 
resulted in a rare event, observed in only one thymic carcinoma.  Similarly, no KIT 
mutations were detected in the 13 TETs sequenced. Reviewing literature data, KIT 
was mutated in only 9% of thymic carcinomas.  
Therefore, a systematic screening for new genomic aberrations in TET was 
started using whole genome sequencing to evaluate the presence of mutations, 
translocation and copy number (CN) aberrations in a B3 thymoma. The translocation 
t(11;X)(q14.2;q25), the presence of 7 single nucleotide mutations and 1 INDEL were 
observed together with CN gain of chromosome 1q, 5, 7, X and CN loss of 3p, 6, 13 
and part of chromosome 11q.  
  ‐ 4 ‐ 
In order to identify which one of these genomic aberrations was recurrent and 
therefore candidate to drive TET growth, whole exome sequencing and array 
comparative genomic hybridization (CGH) were adopted. 26 tumors were screened by 
array CGH and 5 selected to be sequenced using tumor and normal DNA. The 
identified mutations were confirmed and tested for expression using transcriptome 
sequencing. The sequencing demonstrated a remarkably heterogeneous pattern of 
mutations. Recurrent were the amplification of BCL2, observed in 4 thymic 
carcinomas, and the inactivation of CDKN2A caused by a frame-shift INDEL and 2 
CN losses.  
Because BCL2 and CDKN2A are more likely to be mutated by CN 
aberrations, 59 formalin fixed paraffin embedded tumors were evaluated using array 
CGH.  Data confirmed the presence of focal CN loss of CDKN2A and amplification 
of BCL2 as recurrent events in TETs and suggest a possible prognostic role for these 
CN aberrations. Immunohistochemistry confirmed the lack of P16INK4 expression in 
tumors with CDKN2A CN loss and showed a poor prognosis for patients with 
negative staining. P16INK4 is a well-known tumor suppressor gene involved in the 
control of cell cycle through the binding of CDK4 and 6.  
The role of anti apoptotic BCL2 family proteins was elucidated using 3 TET 
cell lines because these molecules could represent targets for therapy. A siRNA 
approach demonstrated that the expression of BCL2 and MCL1, two anti-apoptotic 
proteins, was necessary for TET cell line growth. GX15-070, a BH3 mimetic inhibitor 
of anti-apoptotic BCL2 family members, reduced proliferation of TET cell-lines in 
vitro, through the induction of autophagy and necroptosis. Gx15-070 inhibited tumor 
growth in the xenograft model established using TY82 thymic carcinoma cell line; 
therefore this drug may be tested for patients’ treatment. 
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1. Introduction 
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1.1 Normal thymus  
Macroscopic structure 
The thymus is a median organ located in the anterior mediastinum. Starting 
from fetal life, it increases its dimension reaching maximum size during adolescence 
and decreases thereafter. In the adolescent the thymus extends from the fourth costal 
cartilage upward to the lower border of the thyroid gland. The sternum and the 
sternohyoidei and sternothyreoidei muscles cover the thymus. Back, the thymus 
confines with the pericardium and a layer of fascia, which covers the aortic arch and 
the great vessels. In the neck, it partially wraps the frontal part of the trachea. The 
thymus consists of two lateral lobes that are occasionally united and frequently differ 
in size. This organ presents a soft lobulated surface when cut and a pinkish-gray 
color. 
 
Figure1.1: Normal thymus. (A) Schematic representation of the thymus. (B) 
Microscopic structure of the thymus.  
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Microscopic structure 
A fibrous capsule wraps each lateral lobe of the thymus and protrudes septa of 
a delicate areolar tissue within the organ; therefore it presents a lobular aspect.  The 
lobules vary in size and have an irregular shape being, in the interior portion fused 
together. Each follicle is divided into two main regions on histological grounds, the 
cortex and the medulla; and each of these regions contains several ultrastructurally 
and phenotypically distinct types of thymic epithelial cells and immature lymphocytes 
(thymocytes). 
The thymic cortex is composed by network of epithelial cells mixed with 
abundant thymocytes; these stroma cells form an adventitia to the blood vessels in the 
periphery of lobules.  
In the medulla the epithelial cells are prevalentand are organized in a coarse 
reticulum whereas the thymocytes are relatively fewer in number. Hassall corpuscles 
are nest-like bodies observed in thymic medulla. These corpuscles are composed of 
central granular cells wrapped by several layers of epithelioid cells. The cortico-
medullary junction separates the two distinct portions. Just outside the cortex, the sub-
capsular zone defines a functionally differentiated region of the thymus. 
Stromal cells, mainly thymus epithelium, interdigitating cells, and 
macrophages constitute the thymic microenvironment, but other components, such as 
nerves, endothelium, fibroblasts, and connective tissue are represented as well. 
Distinct regions of the thymus contain different populations of epithelial cells. 
Electron microscopy analyses have identified six types of thymic epithelial cells: type 
1 cells are present in the capsule and septa and surround the perivascular spaces of the 
  ‐ 11 ‐ 
cortical capillaries; types 2, 3 and 4 form a graded series in the cortex, ranging from 
electron-lucent metabolically active to electron-dense dying forms; type 5 cells are 
rare, medullary unspecialized epithelial cells, while type 6 cells form the major 
medullary population and contribute to Hassall’s corpuscles.  
Expression of cytokeratin 5 (K5) and K8 distinguishes epithelial cell 
subpopulations of the thymus. The more prominent cortical and medullary subsets are 
K8+K5– and K8–K5+, respectively. Cells of the cortico–medullary junction are 
K5+K8+. The presence of a common stem cell of endodermic origin, able to generate 
such epithelial subpopulations, has been demonstrated and is characterized by 
MTS20+MTS24+K8+K5+ phenotype1. Therefore, the epithelial component of the 
thymus entirely originates from the endoderm of the third pharyngeal pouch, whereas 
the fibroblast and the capsule originate from mesoderm of the neural crest. The cells 
originating from the neural crest wrap the thymic primordium and this interaction is 
necessary to the normal development of thymus2. Moreover, the precursors of thymic 
epithelial cells are able to start their maturation process but necessitate the interaction 
with thymocytes to differentiate into the mature phenotype3.  
Physiological function of the thymus 
The thymus has a central role in the immune system because it is required for 
T-cell differentiation and repertoire selection. The stromal cells of the thymus sustain 
and drive the maturation of the thymocytes that migrate in this organ from the bone 
marrow. T-cell development is characterized by the progression through several 
phenotypically distinct stages, defined as double negative (DN), double positive (DP) 
and single positive (SP) based on expression of the co-receptors CD4 and CD8. The 
DN subset is further subdivided into four stages (DN1–3 and DN4/pre-DB) by the 
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differential expression of CD44 and CD25. Thymocytes occupy different regions of 
the thymus according to their maturative stages suggesting an highly ordered 
migration (Figure 1.2).  
T-cell precursors access the thymus at the cortico–medullary junction and 
migrate progressively to the subcapsular zone of the outer cortex; thereafter 
thymocytes move back through the cortex and into the medulla, from where they 
egress to the periphery in the form of mature T lymphocytes. Migrating through the 
cortex, thymocytes undergo the positive selection for those cells presenting a T cell 
receptor able to recognize the major histocompatibility complex. Passing through the 
medulla, thymocytes are exposed to the negative selection that removes those T-cell 
precursors able to recognize self-antigens. This process is also known as central 
tolerance and it is promoted by the ectopic expression of tissue-restricted self-antigens 
in the medullary cells of the thymus. The expression of tissue-restricted self-antigens 
mirrors virtually all tissues of the body, irrespective of developmental or spatio-
temporal expression patterns. The autoimmune regulator gene (AIRE) promotes the 
expression of peripheral antigens in medullary cells. The subversion of thymic 
architecture and the abnormal properties of neoplastic thymic epithelial cells in 
thymomas can brake the central tolerance and are considered responsible for the 
increased number of autoimmune diseases observed in these tumors.  
  ‐ 13 ‐ 
 
Figure 1.2: Modified from Blackburn CC, et al.3; the thymic lobule is divided into 
cortex and the medulla. Different types of epithelial cells constitute the stroma of 
thymic medulla (MEC) and cortex (CEC). The thymic cortex has been separated into 
4 regions. In region 1, the cortico–medullary junction, is the site of entry into the 
thymus and contains DN1 cells. In region 2, cells differentiate to the DN2 stage, 
undergo a proliferative clonal expansion, and lose B- and natural killer (NK)-cell 
potential.  In region 3, DN3 cells rearrange their T-cell receptor (TCR) β-chain. In 
region 4 DN cells become CD4+CD8+ DP. DP cells migrate back through the cortex 
to differentiate into the medulla either in CD4+ or CD8+ SP cells. B: B lymphocytes 
and DC: dendritic cells. 
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1.2 Definition of thymic epithelial tumors 
 
Thymoma and thymic carcinoma are neoplasms originating from the epithelial cells 
of the thymus; therefore, they are defined thymic epithelial tumors  to distinguish 
them from lymphomas that arise from thymic lymphocytes and thymocytes (immature 
lymphocytes of the thymus). Levine and Rosai have introduced such distinction in 
19764. Previous publications indiscriminately named thymomas also those tumors 
originating from thymic lymphocytic component. 
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1.3 Epidemiology 
 
 Thymic epithelial tumors (TETs) are the most frequent primary tumors of the 
mediastinum, however they are rare. In the mediastinum, metastases are the most 
commonly diagnosed masses, while primary tumors are among the most rare human 
neoplasms comprising less than 1% of all adult cancers. TETs comprise about 25% of 
primary mediastinal cancers (Figure 1.3 A). 
Three population-based studies have estimated the incidence of TETs in the 
Netherlands, Sweden and USA. According to the Dutch cancer register, the incidence 
of TETs is 0.32/100 000 person-year5, while, according to the Swedish register, 0.23 
in female and 0.27 in male6. In the Nederlands, the incidence progressively increased 
by 6% between 1995 and 2003. Data on US population are more difficult to interpret, 
because the Surveillance, Epidemiology and End Results (SEER) database collects 
only data on malignant thymomas. The definition of malignant thymomas was based 
on an obsolete classification and limited to those cases with capsular invasion. Due to 
the stage at the diagnosis and the evidence of capsular invasion, not all thymomas 
have been captured by SEER registries, because they could be interpreted as benign 
tumors by pathologist or clinicians. Because such cases have not been recorded in the 
US cancer registries, the reported estimated incidence of 0.13/100 000 person-year 
underestimates the global incidence of TETs in US, including only a subgroup of 
cases considered “malignant thymomas”7. Such results come back in line with 
European estimations, considering that 35.5% of TETs were classified malignant and 
64.5% benign in the Swedish population6. 
TETs are exceedingly uncommon in children and young adults; the incidence rises 
in middle age, and peaks in the seventh decade of life. The median age at the 
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presentation is 60 years, with most patients older than 40 years6. Surprisingly, the 
increase in thymoma incidence with age appears in striking contrast to the progressive 
age-related involution of the thymus. Similarly, the incidence decline at the oldest 
ages is unexplained. 
TET incidence is higher in Asians/Pacific Islanders and African Americans than 
Caucasian and Hispanics, among the ethnic groups studied in SEER database7.  
Patients affected by TET present a reduced overall survival6, despite the possible 
indolent behavior of a subgroup of them (Figure 1.3B). Patients with either malignant 
or benign tumors have a shorter survival compared to the control group which was 
constituted by subjects randomly selected from the Swedish population database, 
without any history of cancer and matched by gender and age6.  
 The evaluation of secondary malignancy after the diagnosis of TET is relevant 
to understanding the etiology and the biology of these tumors. An increased risk of 
specific neoplasms could indicate that those cancers share genetic or environmental 
risk factors. Moreover, an elevated risk for specific cancers succeeding thymoma may 
suggest that the immune dysregulation caused by thymoma predisposes to those 
cancers. Retrospective reports suggest a broadly increased risk for cancer in patients 
treated for thymoma, with possible relation to genetic predisposition or to immune 
disturbance. In those studies the frequency of secondary malignancy ranged between 
28 and 8%8-10. In the SEER database, 66 out of 733 (9%) patients with a diagnosis of 
malignant thymoma successively developed a secondary tumor. However, the 
corresponding standardized incidence ratio (SIR)@, that approximates the relative risk 
for cancer associated with thymoma, was only 1.5; which was a more modest 
elevation than that depicted in the hospital-based series7. Among the specific 
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malignancy, only an increased risk for non-Hodgkin’s lymphoma (7 cases) was 
supported by SEER data for a SIR of 4.77. The increased risk for secondary non-
Hodgkin’s lymphoma was confirmed in the Swedish register (SIR 6.3) and reported 
together with an increased risk of non-melanoma skin cancer (SIR 10.6) and cervix 
cancer (SIR 6.9) that were not evaluated in the US study6. These observations have 
been related to the immune system alteration associated with thymic impairment, 
since a significantly risk increase of non-melanoma skin cancer, non-Hodgkin’s 
lymphoma and cancer of the cervix, are strongly associated with severe immune 
disorders such as acquired immunodeficiency syndrome (AIDS). A complementary 
approach can be adopted to examine cancer registry data searching for thymoma risk 
following other primary malignancy. A report, based on SEER data, showed only a 
modestly elevated risk of developing thymoma after different cancers (SIR 1.33), 
without any relation to a particular tumor type11. The lack of an increased risk for 
developing thymoma in non-Hodgkin’s lymphoma patients supports the hypothesis 
that the elevated risk of secondary non-Hodgkin’s lymphoma after thymoma arises 
from immune disturbance consequent to thymoma. Moreover, the absence of an 
increased thymoma risk in lung or breast cancer and in Hodgkin’s lymphoma patients, 
all of which are frequently treated by radiation therapy to the chest, argues against a 
role played by ionizing radiation as a risk factor for thymoma. Such data regarding 
risk of secondary cancers do not suggest tobacco or alcohol as candidate risk factors 
for thymoma. There are not data concerning the role of occupation, environmental 
exposures, or diet and nutrition. 
@ Note: the standardized incidence ratio (SIR) is the ratio of the observed-to-
expected number of cases: if SIR =1 the incidence of secondary malignancy is the 
same of the reference population whereas it is increased when SIR >1. 
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Figure 1.3: Epidemiology data of thymic epithelial tumors. (A) Depicts the frequency 
of primary tumor of the mediastinum in adults. (B) Modified from Gadalla SM, et 
al.6; Survival curves for benign and malignant thymoma patients and their matched 
controls 
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1.4 Etiology 
The etiology of TETs is largely unknown. Based on case-reports, viral 
etiology has been evaluated as a possible cause of TETs. Two cases of human foamy 
virus in patients with thymoma or myasthenia gravis have been reported12,13, however 
subsequent larger studies did not confirm these findings14,15. Similarly, the infection 
of human T-cell lymphotropic virus type 1 has been described in myasthenia gravis 
patients, some of whom had thymoma16, but, again, these findings were not 
confirmed14.  
More convincing evidences indicate Epstein Barr virus (EBV) as a possible 
cause of lymphoepithelioma-like thymic carcinoma, since viral infection has been 
confirmed in these tumors17-20 and its histological features resemble those of 
nasopharyngeal carcinoma: tumors caused by EBV in a subset of patients.  
An higher frequency of neuroendocrine thymic carcinomas has been reported 
in patients affected by Multiple endocrine neoplasm 1 (MEN1) syndrome21,22, 
however, the incidence (8%) of thymic tumors remains an infrequent finding in 
MEN1 patients. About 25% of patients with thymic carcinoids have a positive history 
of MEN123.  
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1.5 Staging  
 Thymomas are an heterogeneous group of tumors according to histological 
features and malignant behavior. There are tumors that present a favorable prognosis 
growing into the thymic capsule; such tumors can even reach large dimensions, up to 
bulky masses, but they remain limited to the thymus borders. Other tumors present a 
more aggressive behavior invading the mediastinal structures. Usually, these more 
aggressive tumors start invading the thymic capsule, thereafter the mediastinal fat and 
finally, infiltrate other mediastinal organs. Diffusion in the pericardial and pleural 
cavities are the most common ways of dissemination. Less frequently, advanced 
thymomas present a metastatic spread colonizing distant organs such as liver, lung or 
bone than regional lymph nodes. On the other hand thymic carcinomas usually are 
aggressive diseases with early invasion of regional structure as well as metastatic 
spread24.  
 To evaluate TETs it is necessary to organize them according to their extent of 
spread, therefore they are classified according a specific staging system. The stage at 
the diagnosis is one of the most important prognostic factors for TETs and contributes 
to define the framework of treatment of these neoplasms. In 1981, Masaoka has 
proposed a staging system that has been widely accepted during the last decades and 
is currently adopted in most centers (Table 1.1). Beside Masaoka staging system, 
recently, several authors have proposed a TNM based classification: Yamakawa and 
Masaoka et al.25, Tsuchiya et al.26 at the National Cancer Center Hospital of Japan, 
the WHO committee24 and Bedini et al.27 at the National Cancer Institute of Italy. The 
TNM schema proposed by Yamakawa and Masaoka is reported in table 1.2. The 
Masaoka staging system empathizes the importance of local invasion and is mainly 
designed for thymomas which present nodal metastasis only in 3.2% of patients28. 
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Conversely, a larger number of thymic carcinomas display nodal spread (32.6%), 
thus, the presence of N1, N2 or N3 diffusion could segregate patients upon survival.  
Kondo et al. have evaluated the prognostic implication of nodal spread among 
the stage IVB in a large series of TETs. However, the authors did not show any 
significant difference. Consequently, they concluded that Yamakawa and Masaoka 
TNM system represents an excellent predictor for the prognosis even in thymic 
carcinomas where the N and/or M influence the prognosis more than the T factor29. A 
proper sub classification of the N and/or M factors necessitates large-scale studies 
including resectable and unresectable tumors29. Therefore, in the flowing chapters 
stages are referred to the system reported in table 11.  
Table 1.1: Masaoka staging system 
I Macroscopically encapsulated tumor, with no microscopic capsular invasion 
IIa Microscopic invasion into the capsule 
IIb Macroscopic invasion into surrounding fatty tissue or mediastinal pleura 
IIIa Macroscopic invasion into neighboring organs without invasion of great vessels 
IIIb Macroscopic invasion into neighboring organs with invasions of great vessels 
IVa Pleural or pericardial metastases 
IVb Lymphogenous or hematogenous metastasis 
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Table 1.2: TNM Classification of Thymic Epithelial Tumors (Yamakawa and Masaoka 25) 
  
         
T factor         
T1: Macroscopically completely encapsulated and microscopically no capsular invasion 
T2: Macroscopically showing adhesion or invasion into surrounding fatty tissue or mediastinal 
pleura, or microscopic invasion into capsule 
T3: Invasion into neighboring organs, such as pericardium, great vessels, and lung  
T4: Pleural or pericardial dissemination      
         
N factor         
N0: No lymph node metastasis      
N1: Metastasis to anterior mediastinal lymph nodes    
N2: Metastasis to intrathoracic lymph nodes except anterior mediastinal lymph nodes 
N3: Metastasis to extrathoracic lymph nodes     
         
M factor         
M0: No hematogenous metastasis      
M1: Hematogenous metastasis      
         
Stage I T1 N0 M0      
Stage II T2 N0 M0      
Stage III T3 N0 M0      
Stage IVA T4 N0 M0      
Stage IVB any T N1-3 M0      
Or any T anyN M1           
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1.6 Histological Classification of thymic epithelial tumors 
 The classification of TETs based upon their histological features has been one 
of the most debated topics between pathologists. In 1961, Barnatz et al. from the 
Mayo clinic presented the first widely accepted classification of TETs by which 
thymomas were divided in four categories: predominantly lymphocytic, 
predominantly epithelial, mixed and predominantly spindle cells. During the 
following years, several subsequent classifications (Table 1.3) have been proposed 
and criticized, until 1999, when the World Health Organization (WHO) committee 
chaired by Dr. Rosai presented a proposal of classification that encountered large 
agreement between pathologists. That proposal has been integrated and accepted as a 
formal classification in 2004 by a WHO committed chaired by Dr. Muller-
Hermelink24,30.  
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 According to this classification, a clear cut distinction has been defined 
between thymomas, organotypic tumors that mimics the structure of normal thymus, 
and thymic carcinomas, more aggressive neoplasms that do not resemble the structure 
of normal thymus but those of carcinomas originating in organs other than thymus.  
  ‐ 25 ‐ 
Gross pathological and histological features of thymic epithelial tumors 
 Thymomas are classified in A, B histotypes, depending on the shape of 
epithelial cells and their nuclei.  
A type thymomas present bland spindle/oval epithelial tumor cells with few or 
no lymphocytes. Grossly, they are usually encapsulated and easily separable from the 
surrounding organs even in case of tumors with conspicuous dimension.  When cut, 
the surface appears white with vague lobulation. Cystic structures and calcification of 
the capsules can be observed. Microscopically, the tumor cells present bland nuclei 
with disperse chromatin and inconspicuous nuclei. Tumor cells are arranged in solid 
sheets without any particular pattern, neither distinct lobules nor dissecting fibrous 
bands typical of other type of thymomas. Type A cells can form cystic o glandular 
structure, glomeruloid bodies, rosettes or meningioma-like whorls. Perivascular 
spaces are less commonly seen than in other types of thymomas and even if type A is 
a thymocyte poor thymoma, spindle cells micronodules in a lymphoid stroma can be 
observed at places. Mitotic figures are infrequent. Necrosis can be appreciated in case 
of lobular infarct. Rarely, thymic carcinoma can arise in type A thymoma, usually 
accompanied by necrotic areas, which examination reveals hyperchromatic anaplastic 
nuclei and or mitotic figures indicating the presence of carcinoma24. 
Type B thymomas show epithelial cells with a predominantly round or 
polygonal appearance and are further classified in B1, B2 and B3, according to an 
increasing degree of atypia of the tumor cells and to a decreasing extent of 
thymocytes24.   
Type B1 thymomas display tumor epithelial cells scattered in a prominent 
population of immature non-neoplastic thymocytes resembling the structure of normal 
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thymus cortex. Usually, B1 thymomas are encapsulated grayish masses. Thick fibrous 
septa protruding from the capsule can be observed, as well as cystic spaces or small 
hemorrhagic and necrotic areas. Microscopically, the neoplastic epithelial cells are 
scant, small, with very little atypia and submerged by non-neoplastic thymocytes. The 
tumor cells are oval with pale round nuclei and small nucleoli, although some cells 
may be large and occasionally have conspicuous nucleoli. B1 thymomas are usually 
organized in a lobular structure even if sheets architectures can be sometime 
appreciated. Either thick or thin fibrous bands separate lobules of various sizes. 
Perivascular spaces are not as frequent as in other B thymomas. Pale areas of 
medullary differentiation are always present, composed of more loosely packed 
thymocytes; Hassall’s corpuscles are less frequent than in medulla of normal 
thymus24.  
Type B2 thymomas are characterized by large polygonal epithelial tumor cells 
arranged in a loose network containing numerous immature T lymphocytes. Grossly, 
B2 thymomas can be encapsulated, circumscribed or invasive of the surrounding 
tissues and organs. When cut, the surface presents tan-colored nodules separated by 
white fibrous septa and can be soft or firm. Cysts, hemorrhages and fibrosis can be 
appreciated. Microscopically, the large polygonal tumor cells present large nuclei 
with an open chromatin pattern with prominent central nucleoli. Commonly, B2 
thymomas are organized in large lobules with delicate septa, resembling the normal 
architecture of thymic cortex. The tumor epithelial cells form palisades around 
perivascular spaces and along septa, large sheets of tumor cells occasionally can be 
observed. Medullary islands are missing or infrequent and Hassall’s corpuscles are an 
exceptional finding. Tumor cells are usually outnumbered by non-neoplastic 
immature lymphocytes24.  
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 B3 thymomas are composed from medium size round or polygonal epithelial 
tumor cells with slight atypia; these cells are mixed with a minor component of 
intraepithelial thymocytes. Commonly, B3 thymomas are not encapsulated and 
present an infiltrative border with extension to the mediastinal fat or the surrounding 
organs. The cut surface appears firm and lobulated in grey and white nodules by 
fibrous septa. Soft yellow or red foci, cyst formation or hard calcification are common 
both in large and small tumors. Usually, neoplastic cells are polygonal with round or 
elongated nuclei often folded or grooved. Commonly, B3 cell nuclei are smaller and 
with less prominent nucleoli than in B2 thymomas. In a minority of cases, more 
atypical, enlarged and hypercromatic nuclei are observed. Other rare variants present 
either polygonal cells with nuclei similar to B2 thymomas or partial clear cell 
changes. Focal or extensive structure of spindle cells can be observed. B3 thymomas 
with anaplasia are a small group of tumor showing an high degree of atypia but 
conserving the organoid structure of thymomas. Tumor cells form lobules that are 
separated by thick fibrous and hyalinized septa. Tumor cells grow in palisades around 
perivascular spaces and along septa resulting in the formation of tumor cell sheets 
with a vaguely solid or epidermoid appearance24.  
 AB thymomas are composed of a lymphocytes-poor type A and a more 
lymphocyte-rich type B component. Usually, AB thymomas are encapsulated. The cut 
surface shows a lobular structure divided, by fibrous septa, in tan colored nodules of 
variable sizes. All the histological features of type A thymomas are represented in the 
A component. Conversely, the B component is peculiar and differs from B1, B2 or B3 
thymomas; it is characterized by small polygonal tumor cells with small round, oval 
or spindle nuclei showing disperse chromatin and small nucleoli. The A and B 
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components either form discrete separate nodules or intermix together. The growth 
pattern consists of nodular and diffuse areas24.  
 The 2004 WHO classification depicts separate additional categories:  the 
micronodular thymoma with lymphoid stroma, the metaplastic thymoma and a group 
of rare thymomas. Micronodular thymoma is characterized by cystic tumor areas of 
variable size and by multiple discrete or confluent nodules of epithelial cells, 
separated by lymphocytic stroma that might contain follicles with germinal center. 
Tumor epithelial cells of microcystic thymoma are slender or pulp spindle with bland 
looking oval nuclei and small nucleoli. Metaplastic thymomas do not present a 
lobulated growth pattern and are characterized by a biphasic architecture comprising 
epithelial islands intertwining with boundless of spindle cells. The tumor cells are 
polygonal, ovaloid or plump spindle, with oval vesicular nuclei, small distinct 
nucleoli and an amount of lightly eosinophilic cytoplasm. Rare thymomas are 
defined: microscopic thymoma, sclerosing thymoma and lipofibroadenoma of the 
thymus, a neoplasm that occasionally occurs adjacent to a conventional type B1 
thymomas. Microscopic thymoma depicts the multifocal proliferation (<1mm in 
diameter) that can occur in the thymus of myasthenia gravis patients without a 
macroscopically evident tumor. The sclerosing thymoma exhibits the features of a 
conventional thymoma in terms of epithelial cell morphology and thymocytes content, 
but with an exuberant collagen rich stroma24.  
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Table 1.4: Thymoma histotypes        
Type A     
Type AB     
Type B1    
Type B2    
Type B3     
Micronodular thymoma    
Metaplastic thymoma    
Rare thymomas     
 Microscopic thymoma    
 Sclerosing thymoma    
 Lipofibroadenoma of the thymus    
 
 Thymic carcinomas regroup all non-organotypic malignant epithelial 
neoplasms other than germ cell tumors. Carcinomas are named according to their 
differentiation and are listed in table 1.5. 
Table 1.5: Thymic carcinoma histotypes        
Squamous cell carcinoma     
Basaloid carcinoma     
Mucoepidermoid carcinoma     
Lymphoepithelioma-like carcinoma    
Sarcomatoid carcinoma     
Clear cell carcinoma     
Papillary adenocarcinoma     
Non-papillary adenocarcinoma    
Carcinoma with t(15;19) translocation    
Undifferentiated carcinoma of the thymus   
Thymic neuroendocrine tumors     
 Well differentiated neuroendocrine carcinomas  
  Typical carcinoid   
  Atypical carcinoid   
 Poorly differentiated neuroendocrine carcinomas  
  Non-small cell neuroendocrine carcinoma 
    Small cell neuroendocrine carcinoma 
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Figure 1.4: microscopy appearance of thymic epithelial tumors according to their 
histotype. Images were captured at 20x magnifications. 
 
Squamous cell carcinoma of the thymus is a tumor of the epithelial cells of the 
thymus resembling the features of those squamous cell carcinomas originating in 
organs other than thymus. Squamous cell carcinomas at the diagnosis usually 
infiltrate the surrounding organs and tissues. At the cut surface, lobulation and fibrous 
septa are not evident, whereas foci of necrosis and hemorrhage are common features. 
Tumor cells are large polygonal with or without evidence of keratinization and 
presenting vesicular or hyperchromatic nuclei. Cells are arranged in nests and cords 
divided by fibrohyaline-stroma24.  
 Basaloid carcinoma is composed by compact lobules of tumor cells with 
peripheral palisading and a basophilic staining pattern due to a high nuclear-
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cytoplasmatic ratio. Basaloid carcinoma frequently originates in micronodular thymic 
cysts. Generally, basaloid carcinomas are well-circumscribed, grey masses 
surrounded by a thin fibrous capsule with focal hemorrhage and cystic formations. 
Microscopically, the cells are small, columnar, round or spindle with hyperchromatic 
round nuclei, scant cytoplasm and indistinct borders24. 
 Mucoepidermoid carcinoma is a rare variety of thymic carcinomas 
characterized by the presences of squamous cells and cells producing mucous. The cut 
surface of these tumors looks nodular with fibrous bands and mucinous appearance24.  
Lymphoepithelioma-like carcinoma is characterized by a sincitial growth of 
undifferentiated carcinoma cells accompanied by lymphoplasmacytic infiltration. It 
may or may not be associated with EBV infection. Macroscopically, the tumor is solid 
with yellow/white areas of necrosis. The tumor cells present large vesicular nuclei 
with open chromatin and show indistinct plasma membrane. Lymphocytes are 
admixed with the carcinoma cells, that growth in nests or anastomosing cords24. 
  Sarcomatoid carcinoma resembles soft tissue sarcoma morphology and, 
usually, is constituted by a sarcomatoid and a carcinoma component. The 
carcinomatous component comprises clusters and sheets of poorly differentiated 
epithelial cells with nuclear prominent atypia and occasional squamous 
differentiation. Spindle tumor cells with pleomorphic nuclei characterize the 
sarcomatoid component, these cells show distinct nucleoli and frequent mitotic 
figures organized in fascicules and storiform arrays24.  
Clear cell carcinoma is a rare variety composed from polyhedral tumor cells 
with optically clear cytoplasm with slight cellular pleomorphism and nuclear atypia. 
Tumor cut surface shows solid or cystic regions without any evidence of hemorrhage 
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or necrosis. Tumor cells grow in nests, lobules or sheets surrounded by a dense 
fibrous stroma that confers a lobular architecture24.  
Papillary adenocarcinoma is rare and characterized by a prominent papillary 
pattern of growth. Tumor cells have eosinophilic clear cytoplasm and round ovaloid 
nuclei with condensed chromatin and few small prominent nucleoli. Few cells are 
positive for mucine stating. Tumor cells grow in tubulopapillary structure of uniform 
cuboid to columnar cells, mainly lying in a monolayer but occasionally showing a 
glomeruloid arrangement. Non-papillary adenocarcinoma differentiation of thymic 
carcinoma is more extremely rare with only three cases described in literature24.  
Carcinoma with t(15;19) translocation is a rare carcinoma of unknown 
histogenesis arising in the mediastinum and other midline organs of young people. 
Undifferentiated cells, vigorously mitotic, grow in sheets that form syncytia with inter 
epithelial lymphocytes24.  
Undifferentiated thymic carcinomas are characterized by a solid growth of 
undifferentiated cells. The diagnosis is one of exclusion with other primary sites24.  
Thymic neuroendocrine carcinomas are predominantly or exclusively 
composed of neuroendocrine cells and have to be distinguished by those thymic 
carcinomas that may contain scattered groups of neuroendocrine cells. The 
neuroendocrine differentiation of epithelial tumor cells can be demonstrated by 
immunohistochemistry when positive for chromogranin, synaptophysin NSE and 
CD56. These tumors are sub-classified in well-differentiated neuroendocrine 
carcinomas: typical and atypical carcinoid and poorly differentiated neuroendocrine 
carcinomas: small cell and large cells neuroendocrine carcinomas. Grossly, they are 
frequently invasive at the diagnosis and on the cut section are firm, grey-white or tan 
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with a gritty consistency. Typical carcinoids are devoid of necrotic area and exhibit a 
low mitotic rate (<2 mitosis in 2mm2); conversely to the more common atypical 
carcinoids that display either necrosis or 2-10 mitosis in 2mm2. Large cells 
neuroendocrine carcinomas present more than 10 mitoses in 2mm2; whereas, small 
cell neuroendocrine carcinomas are characterized by small size round, oval or spindle 
cells with very scant cytoplasm and high mitotic activity24.  
 Finally, the 2004 WHO classification introduces the combined TETs, with at 
least two distinct areas each corresponding to one of the histological thymoma and 
thymic carcinoma types. The description and the frequency of these combined tumors 
underlines the morphological heterogeneity that TETs can display. Moreover, this can 
partially explain the limited reproducibility of histological classification and the 
difficulty to predict prognosis upon morphological appearance24.  
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Clinical relevance of WHO classification 
 Difference between thymomas and thymic carcinomas is relevant for the 
clinical practice mainly because thymic carcinoma exhibits a more aggressive 
behavior and is infrequently paraneoplastic syndromes.  
B2 and AB are the most common thymomas, whereas, A and B1 are less 
represented (Table 4). Myasthenia gravis (MG) and red pure cell aplasia have been 
reported in all kind of thymomas, even if, with a different frequency of association. 
Paraneoplastic hypogammaglobulinemia and Good syndrome were described in B 
tumors. For all histotypes, symptoms at the diagnosis can be either related to 
paraneoplastic syndromes or consequent to the presence of a mediastinal mass24. In 
type A, AB and B1 the diagnosis is frequently incidental, being the patients 
asymptomatic. Usually, B2 and B3 tumors manifest themselves with local symptoms 
such as chest pain, cough or dyspnea up to vena cava syndrome as they tend to be 
invasive due to their more malignant behavior. At the diagnosis, A and AB thymomas 
are usually circumscribed at the stage I or II (Table 1.6) and show a favorable 
outcome with survival reported up to 100% at 10-year24 (Table 1.7). B1 thymomas 
present limited malignant behavior; more than 90% of tumors are resectable and local 
recurrences or late metastases occur in less than 10%24. Consequently, B1 thymoma 
10-year survival is about 90%24. Conversely, B2 and B3 thymomas are more 
malignant tumors with reported 10-year survival between 100-50% and 70-50%, 
respectively24. 3% of B2 and 7% of B3 thymomas are metastatic at the diagnosis. 5-
15% of B2 and 17-47% of B3 are not resectable at presentation. After surgery, B2 and 
B3 thymomas present local recurrence in 5-9% and 15-17% and metastasize in 11% 
and 20% of cases, respectively. Such data support a prognostic segregation of low 
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malignant grade tumors (A, AB and B1) and intermediate grade malignant 
neoplasms24 (B2 and B3; Figure 1.5).  
Micronodular thymomas are 1-5% of TETs that occur at a mean age of 58 
years and are rarely associated with paraneoplastic syndromes (<5%). Micronodular 
thymoma outcome is usually favorable due to stage I diagnosed in more than 90% of 
patients. Only few cases of metaplastic thymomas have been described, none of them 
associated with paraneoplastic syndromes.  Metaplastic thymoma diagnoses were 
incidental with 75% of the tumor stage I24.  
 Thymic carcinomas are 10-20% of TETs; they are frankly aggressive 
neoplasms with a 10-year survival <50%. At the diagnosis, most tumors are stage III 
and IV24.  Rare paraneoplastic polymiosites but not MG have been described in 
thymic carcinomas. The most frequent thymic carcinomas are those with squamous 
cell differentiation; 90% in Asian and 30% in western series. Undifferentiated 
carcinoma is the second most common and it is characterized by a more severe 
prognosis24. Basaloid carcinomas are rare with few cases described; they show a 
remarkable tendency to originate in multilocular thymic cysts and are characterized 
by a less malignant behavior24. The remaining subtypes of thymic carcinoma are 
considerably rare and their description is mainly based on case reports. Out of these 
tumors lymphoepithelioma-like and clear cell carcinomas present a remarkable 
aggressive behavior. Only 6 cases of carcinomas with the translocation t(15;19) have 
been described for which a thymic origin has been postulated24. These belong to a 
group of neoplasom named midline tumor, characterized by a remarkably aggressive 
behavior, a young age of insurgence and the fusion of NUT gene with BRD4 in 2/3 of 
cases and with BRD3 or with unknown partners in the reaming24.  
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 Neuroendocrine thymic carcinomas are 2-5% of TETs; most of them are 
atypical carcinoid. Rare small cell neuroendocrine carcinoma and exceptionally rare 
typical carcinoid and large cell neuroendocrine carcinoma have been described24. 
Outcome is more favorable for atypic carcinoid 84% and 75% at 5 and 10-year 
survival, respectively24. 30-50% of small cell neuroendocrine carcinomas are 
diagnosed in stage IV. Small cell neuroendocrine carcinomas present a severe 
prognosis with 5 and 10-year survival of 50 and 30%, respectivelly24. Symptoms at 
the presentation can be related to the mediastinal mass or to the correlated endocrine 
syndromes. The most frequently observed endocrine syndromes are ACTH induced 
Cushing, present in 17-30% of adults and >50% of children, acromegaly, 
hypercalcemia/hypophosphatemia whereas carcinoid syndrome is rare (<1%).  25% of 
thymic neuroendocrine carcinomas present a MEN1 syndrome and 8% of patients 
affected by MEN1 syndrome present a neuroendocrine thymic carcinoma24.  
 
Table 1.6: WHO histotypes and stage at the diagnosis 
Histotype  Stage   Survival 
 I II III IV 10-year 
A 80% 17% 3%  100% 
AB 71.70% 21.60% 5.60% 1.10% 80-100% 
B1  53-58% 24-27%  90% 
B2 10-48% 13-53% 19-49% 8.90% 50-100% 
B3 4.20% 15-38% 38-66% 6-26% 50-70% 
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Table 1.7 Histotypes’ characteristics  
Histotype Prevalence Mean age Myasthenia gravis 
A 4-19% 61 24% 
AB 15-43% 55 14% 
B1 6-17% 41-47 18-56% 
B2 18-42% 47-50 30-82% 
B3 7-25% 45-50 30-77% 
 
 
 
 
 
Figure 1.5: modified from Chen et al.31 (A) Overall survival reported for each 
histological subtype. Type B2-3 and C thymomas have a significantly (P=0.001) 
increased risk of death. (B) Overall survival of stage I and II tumors (n 102). There 
were two deaths among patients with Type A, AB, and B1 thymomas (n 78), but four 
deaths in patients with Type B2, B3, and C thymomas (n 24). The difference is 
statistically significant (P =0.003) 
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Reproducibility of WHO classification 
 The 2004 WHO, as well as previous classifications, presents disputed issues 
regarding reproducibility and its prognostic value.  The inter observer agreement has 
been evaluated using the material described in the chapter 3.5 and is currently under 
consideration for publication but do not represent a result of this dissertation. Briefly, 
a series of 132 TETs has been reviewed by 3 independent pathologists at 3 different 
institutions Humanitas Cancer Center (Rozzano-Milan, Italy), Seoul National 
University Bundang Hospital, Seongnam-si (Gyeonggi, Republic of Korea) and 
National Institute of Health (Bethesda, MD) and compared to the original diagnosis 
(CLAS1). The aims of this comparison were to evaluate the reproducibility of the 
WHO schema and determine if reproducibility can affect its prognostic value. The 
original histological diagnosis reported after surgery, paraffin blocks and slides, as 
well as clinical history were available in 129 cases. For this analysis combined 
thymomas were re-classified according to the more aggressive histotype (for example 
B2-B3, were considered B3 thymomas). 
Table 1.8 summarizes histotype frequencies according to the 4 observers. The global 
agreement was moderated; taking into consideration all the WHO histotypes and all 
the pathologists at the same time: Fleiss’ kappa coefficient 0.53. To compare 
agreement between different pathologists, Cohen’s Kappa coefficient was calculated 
for each comparison pair (Table 1.9). The best agreement was observed between 
CLAS2 and CLAS1 (K coefficient: 0.84). A substantial agreement was also observed 
between CLAS3 and CLAS2 (K coefficient: 0.70) and CLAS3 and CLAS1 (K 
coefficient: 0.64). A moderate strength of agreement was observed between CLAS4 
and each of the other three observers, with a Kappa correlation coefficient ranging 
from 0.52 to 0.53. In 63/129 (48.8%) cases there was a complete agreement among 
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different observers. In 43/129 (33.3%) cases three out of four pathological diagnoses 
were identical; in 15/129 (11.6%) cases the diagnoses were identical by pair; in 8/129 
(6.2%) cases three different pathological diagnoses were reported; complete 
disagreement (four different diagnoses) was never observed. More frequently (9/23, 
39%) the discordant diagnosis interested B thymomas, especially the discrimination 
of B1 and B2 (6/9). In 6/23 (26%) cases, the diagnostic discrepancy involved type AB 
thymomas versus B thymomas. In 7/23 (30%) cases, inconsistency regards fairly 
different histological subtypes: 4 cases of thymic carcinoma vs. type B3; 2 cases type 
B3 vs. type A; and in one case thymic carcinoma vs. type A. 
The interpretations of 2 different pathologists (CLASS1 and CLASS4) were able to 
predict prognosis in univariate analysis of time to progression (TTP; CLAS1 p=0.001; 
CLAS4 p<0.001) and disease relate survival (DRS; CLAS1 p=0.039; CLAS4 
p=0.027).  
Previous reports have evaluated the reproducibility of WHO classification and have 
described an high agreement strength between pathologists interpretation (Kappa 
coefficient 0.9-0.8731,32, respectively). Chen et al.31 have reported inter-observer 
agreement between pathologists from different institutions after a training 
introduction from Dr. Muller-Hermelink; whereas in Riekel et al. evaluation included 
pathologists from the same background. Our results are in line with these reports 
when referred to pathologists of similar backgrounds: CLAS1 and CLAS2 were 
evaluated within the Humanitas Cancer Center and showed a high agreement 
K=0.84). Conversely, among pathologists of different backgrounds, the 
reproducibility was only substantial or moderate. Similarly, the evaluation of 95 TETs 
from 17 pathologists from UK and the Netherlands demonstrated a moderate 
agreement (K=0.45)33.  
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These data denote the importance of a proper training for an acceptable 
reproducibility of the WHO classification. The most challenging diagnoses appear to 
be those discriminating between B1, B2 and AB thymomas in most of the reports. 
Consequently, more clear and defined criteria needs to be established for these 
histotypes. The discrimination of B2 from B1 and AB tumors is relevant for clinical 
practice because of their more severe prognoses; consequently, the prognostic value 
of WHO were, in our series, subject to variation according to pathologist 
interpretations.  
Suster and Moran30 proposed an exemplified classification in order to increase 
reproducibility and better predict prognosis. Table 1.3 summarized this classification. 
However, the WHO classification better highlights the morphological differences 
between TETs and, even if it seems to be of limited immediate clinical interest, it is 
remarkably important for research purpose. Thus, we are going to demonstrate that 
different WHO histotypes present different genomic background and may necessitate 
different targeted therapeutic approaches in the results section.  
 
 
Table 1.8: WHO histotypes according to classification of 4 different pathologists 
 A AB B1 B2 B3 TC 
CLAS1 16.4% 21.1% 17.2% 15.6% 21.1% 8.6% 
CLAS2 11.6% 20.2% 19.4% 13.9% 25.6% 9.3% 
CLAS3 12.7% 19.8% 17.5% 15.9% 19.0% 15.1% 
CLAS4 17.6% 19.2% 3.2% 33.6% 18.4% 8.0% 
CLAS: Pathologist’s classification  
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Table 1.9: Kappa correlation coefficient between each pathologist pair 
 CLAS1 CLAS2 CLAS3 CLAS4 
CLAS1  0.84  (0.77-0.91) 
0.64 
(0.55-0.74) 
0.52 
(0.41-0.62) 
CLAS2   0.70 (0.61-0.79) 
0.52 
(0.41-0.62) 
CLAS3    0.53 (0.43-0.63) 
CLAS = pathologist’s classification; 95%CI was reported with each coefficient in 
parenthesis. The agreement’s strength of reputed: low: <0.41; moderate: ≥0.41<0.61; 
substantial: ≥0.61<0.81; high: ≥0.81. 
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1.7 Treatment of thymic epithelial tumors 
Surgery is the mainstream of treatment for TETs and completeness of 
resection is the goal of the therapy, being the most relevant prognostic factor24. 
Neoadjuvant chemotherapy can improve the rate of radical resection in stage III 
patients who are not eligible for a complete resection34. If a radical resection is not 
achieved by surgical treatment, postoperative radiotherapy can reduce tumor 
recurrences. Although, the efficacy of adjuvant radiotherapy in radically resected 
patients is still controversial, many clinicians adopt such treatment. In patients 
experiencing tumor relapse, salvage surgery is often practicable but depends on the 
site and the number of lesions. Metastatic or not operable patients are treated by 
systemic chemotherapy with a palliative intent.  
Surgery 
A complete resection is usually practicable in stage I (100%) TETs and it is 
sufficient to be curative in the vast majority of patients. Conversely, the resectability 
rate conspicuously varies among reports in infiltrating thymomas: 43-100% for stage 
II, 0-89% for stage III and 0-78% for stage IV35. However, the reported survival is 
more favorable than that observed for other thoracic tumors (Table 1.10). The 15-year 
overall survival is 78% for stage I, 73% for stage II, 30% for stage III and 8% for 
stage IV36. The completeness of resection can not be achieved in all stage III and IV 
patients despite a carefully selection and a proper diagnostic workup. Relapse rate and 
disease free survival measure the effectiveness of surgical treatments and are 
summarized in Table 1.10 and Figure 1.6. Five years is the average time to 
recurrence, although relapses have been described up to 32 years later36. Stage I 
patients tend to recur later (mean 10 years) compared to infiltrative stages (mean time 
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to relapse 3 year)36. Among all recurrences the large majority are local (average 81%), 
whereas distant metastases occur in 9%. 10% of patients presented concomitantly 
with both local and distant relapses36. 
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Table 1.10: Overall Survival of Patients With Thymic Tumors 
  
   % 5-year Survival % 10-year Survival 
  n % R0 I II III IV I II III IV 
Kondo and Monden28 924 92 100 98 89 71 100 98 78 47 
Regnard et al.36 307 85 89 87 68 66 80 78 47 30 
Maggi et al.37 241 88 89 71 72 59 87 60 64 40 
Verley and Hollmann38 200  85 60   80 42   
Nakahara et al.39 141 80 100 92 88 47 100 84 77 47 
Wilkins et al.40 136 68 84 66 63 40 75 50 44 40 
Blumberg et al.41 118 73 95 70 50 100 86 54 26  
Quintanilla-Martinez et al.42 116 94 100 100 70 70 100 100 60  
Pan et al.43 112 80 94 85 63 41 87 69 58 22 
Elert et al.44 102   83 90 46           
 Average 83 92 82 68 62 88 71 57 38 
 
 
 
 
Figure 1.6: Modified from Sakamoto M, et al.45. Disease free survival reported 
according to Masaoka’s stage after extended thymectomy. Survival for Stage III 
disease was significantly worse than that for Stage I (P = 0.0002) and Stage II (P = 
0.002). 
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Subtotal resection 
Despite neoadjuvant treatments, a complete resection can not always be 
planned. The advantages offered by a subtotal resection are still debated because of 
the inconsistence of reports and trial methodology limitations. Authors have reported 
either no advantage for debulking surgery46,47 or an increase of 5-year overall survival 
about 30%28,37,39,48. However, a subtotal surgical resection is indicated for the relief of 
symptoms. Adjuvant treatments should be considered after an incomplete resection.  
 
Salvage surgery 
In those cases experiencing a relapse, the re-intervention is a valuable option 
because many recurrences are local and some of them can be radically removed by a 
salvage surgery. Increase of 5-year survival has been reported up to 40-50% beside 
some negative studies41,49-53. Although, in those cases presenting unique or few local 
metastases re-intervention is a valid option but it is not the standard treatment for 
those cases experiencing extensive pleural dissemination. The chance of resection of 
pleural implants is sometime feasible but has still to be considered an experimental 
procedure54.    
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Radiotherapy  
Radiotherapy has been proposed with different intent in TETs either in 
neoadjuvant, adjuvant, in incompletely resected tumors or as exclusive treatment. 
Currently, the preferred modality of administration is conformal radiotherapy with 
respiratory gating. The use of intensity modulated radiotherapy (IMRT) is encouraged 
and consists of a real-time modeling of the contours and the amount of photons 
delivered within the radiation beam, using a programmed movement of the blades of 
the collimator55. The dose to be delivered varies according to the purpose of the 
treatment. It has been suggested to deliver to the thymic area a total dose of 45 Gy in 
a neoadjuvant setting, 45 to 55 Gy in an adjuvant setting, and 60 to 66 Gy as an 
exclusive treatment using a standard fractionation scheme (one 1.8- to 2-Gy fraction 
per day)55. Patients with TETs localized in the mediastinum, but not eligible for 
surgery, can be considered for radiotherapy that is rarely exclusive being more 
frequently associated with chemotherapy56. Neoadjuvant radiotherapy aim is to 
increase the rate of complete resections. Neoadjuvant radiotherapy can induce 
response in up to 80% of treated patients, thus, a radical resection can be achieved in 
50-75% of cases56. Despite its promising results, the role of neoadjuvant radiation 
therapy remains controversial being currently preferred neoadjuvant chemotherapy 
followed by adjuvant radiotherapy55. Because thymomas are considered radiosensitive 
tumors and they tend to relapse locally, postoperative radiotherapy has been evaluated 
in several studies. 
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Postoperative radiotherapy. 
 Postoperative radiotherapy has been offered for adjuvant treatment of 
completely resected tumor or to consolidate results of subtotal resections. Because 
stage I thymomas relapse in about 2% of cases, adjuvant radiotherapy is not 
recommended for these patients. The role of adjuvant radiotherapy in R0 resected 
stage II and III thymomas remains controversial because the rarity of the disease, 
reports are heterogeneous, include a limited number of cases and are not prospectively 
designed. In 2009, a meta-analysis evaluated the role of adjuvant radiation therapy in 
stage II and III radically resected tumors that were included in retrospective studies 
reporting a control arm of exclusively surgically treated patients.  Among stage II, 
273 patients received a radical surgical resection and 197 a radical resection plus 
adjuvant radiotherapy; relapse were observed in 11 and 8% of cases, respectively 
(Figure 1.7A). Out of the radically resected stage III patients, 53 received adjuvant 
radiotherapy and 69 did not; the relapse rate was 32% and 26%, respectively (Figure 
1.7B). Significant overall survival improvement was not achieved for the patients who 
received adjuvant radiotherapy neither a different pattern of relapse, in favor of 
distant metastases, was described for treated patients57. The analysis of SEER 
database has revealed a survival advantage for those stage II and III patients who 
underwent adjuvant radiation therapy. However, in the same evaluation, patients 
completely resected did not benefit by the adjuvant radiotherapy57. Moreover, 
mediastinal radiation frequently can present both short and long term adverse events 
including, but are not limited to, secondary malignancies, pulmonary fibrosis, 
esophageal strictures, coronary disease, cardiac valvular fibrosis, and pericarditis57. 
Although, the role of adjuvant radiotherapy in stage II and III is discouraged by data, 
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it is currently recommended by many clinicians for stage III patients with more 
aggressive histotypes (B2, B3 and TC)56.  
 Postoperative radiotherapy is systematically recommended after a subtotal 
resection58, including the boost in areas of macroscopic invasion. Radiotherapy has 
consistently decreased recurrence rates from 60-80% to 21-45% after a R1 or R2 
resection28,53,59-64. Frequently, after local recurrence salvage surgery is practicable but 
for those cases not operable or resectable radiation therapy could be a valuable option. 
Small retrospective series depicted promising response rates and 5-year survival rate 
of 70-80%53. 
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Radiotherapy for thymic carcinoma 
 Peculiar considerations are appropriate for thymic carcinomas because theirs 
more pronunced aggressive behavior. Thymic carcinomas frequently are diagnosed 
when invasive and neoadjuvant chemo-radiotherapy may represent a potent approach 
to downstage unresectable tumors55. Although, the role of radiotherapy is expected to 
be more relevant in thymic carcinoma than in thymoma because the minor importance 
of the surgery, Kondo K., et al.28 did not show any significant advantage for the 
adjuvant treatment. In the 186 thymic carcinomas underwent radical resection, 5-year 
survival rate was 74% after adjuvant radiotherapy and 72% after surgery alone. 
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Figure 1.7: Modified from Korst RJ et al.57 Forest plot generated using extracted 
recurrence data for patients with stage II (A) and stage III (B) TET. The squares 
represent the odds ratios of the individual studies, and the size of the squares reflects 
the calculated weight of the study in the meta-analysis. The horizontal bars running 
through each square represent the 95% confidence interval (CI). Studies had been 
weighted and the Diamond at the bottom of the plot illustrates the combined odds 
ratio using a fixed effects model. 
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Systemic therapy  
Thymomas are reputed chemo-sensitive tumors. Thus, chemotherapy is 
indicated either with neoadjuvant or palliative intent.  
Palliative chemotherapy 
 Chemotherapy is indeed the treatment of choice for patients with metastatic 
disease or with unresectable diffuse disease and recurrences. The intent of systemic 
treatment is to delay as much as possible tumor progression and eventually to reduce 
disease related symptoms. Conventional chemotherapeutic such as platinum based 
drugs (Cisplatin and Carboplatin), anthracyclines (Doxorubicin and Epirubicin), 
alkylating agents (Cyclophosphamide and Ifosfamide), vinca alkaloids, Etoposide and 
Pemetrexed have shown activity in TETs. Combination schedules have shown more 
encouraging results when adopted for the first line treatment (Table 1.11). Thus, 
schedules containing platinum and anthracyclines induce response rate from 50 to 
92%. Since TETs, and especially thymomas, frequently present a slow rate of growth, 
multiple subsequent lines of chemotherapy are commonly offered to patients after 
disease progression. Responses to second or further chemotherapy lines are reported 
in up to 40% (Table 1.11). Therefore, overall survival improvement conferred by a 
single schedule is often difficult to understand. Although, thymomas frequently 
respond to chemotherapy, thymic carcinomas are much more resistant tumors. 
Interesting results in thymic carcinoma (response rate 30-24%) have been obtained by 
the combination of carboplatin and paclitaxel (Table 1.11).  
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Table 1.11: Chemotherapy regimes for palliative therapy of thymic epithelial tumors 
References Schedule Line WHO Stage N Pz RR (%) SD 
Median 
TTP(m) 
Median 
OS(m) 
Kunitoh H65 
Dose 
dense 1 T 27 IVA(22) 27 16PR  37% 9,5 73.2 
 Cisplatin   IVB(8)  (59%)    
 Doxorubicin        
 Vincristine        
 Etoposide         
 G-CSF         
Loehrer PJ66 Cisplatin 1 T 29 III 30 3CR, 12PR 33% 18.4 38.4 
 Doxorubicin TC 1 IV  (50%)    
 Cyclophosphamide        
Fornasiero A67 Cisplatin 1 T 37 III (12) 37 16CR, 18PR 5% 12 21 
 Doxorubicin   IV (25)  (92%)    
 Vincristine         
 Cyclophosphamide        
Grassin F68 Cisplatin 1 T 12  III(8) 16 4PR 75% 13.1 nr 
 Ifosfamide  TC 4 IVA(1)  (25%)    
 Etoposide   IVB(7)      
Loehrer PJ69 Cisplatin 1 T 20 III(6) 28 9PR 61% 11.9* 31.6 
 Ifosfamide  TC 8 IVA(13)  (32%)    
 Etoposide   IVB(9)      
Giaccone G70 Cisplatin 1 T 16 III(6) 16 5CR, 4PR 44% 39 51 
 Etoposide   IV(10)  (56%)    
Bjerrum OW71  Cisplatin 1   III(3) 9 1CR, 1PR 56% Uk Uk 
 Vincristine   IVA(3)  (22%)    
 Lomustine   IVB(3)      
 Cyclophosphamide        
 Prednisone         
Furugen M72 Carboplatin 1 TC 16 IVA(4) 16 2CR,  50% 8.6 49.4 
 Paclitaxel   IVB(9)  (38%)    
Lemma GL73 Carboplatin 1 T 21 III (7) 44 3CR, 5PR 48% 19.9 nr 
 Paclitaxel  TC 23 IV (37)  5 PR  52% 6.2 15 
Loehrer PJ74 Pemetrexed ≥2 T 16 IVA(16) 27 2CR,  20% 11.3 65 
   TC 11 IVB(11)  2PR    
Bonomi PD75 Cisplatin ≥2 T(20)   20 2PR (10%) 40%   19 
Palmieri G76 Capecitabine ≤2 T(12) IVB(15) 15 3CR,  3PR 40% 11 nr 
 
Gemcitabine 
  TC(3)      (40%)    
Line was 1 for naïve and ≥2 for previously treated patients. * months median duration 
response, T=Thymoma, TC=Thymic carcinoma; N Pz=number of patients; RR 
response rate, CR complete response; PR partial response, SD stable disease; 
TTP=time to progression in months; OS overall survival in months; Uk unknown, nr 
not reached. 
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Neoadjuvant chemotherapy 
Mostly cisplatin-based regimens have been adopted for neoadjuvant down-
staging of stage III and IVa TETs. The aim of neoadjuvant chemotherapy is to induce 
shrinkage of locally advanced tumors in order to increase the rate of complete 
resection. Authors have reported promising results (Table E 1.12), despite the relevant 
inter-trial variability. The inconsistence of the results was probably due to the 
different proportion of stage III and IV patients, to the presence or not of thymic 
carcinomas, to the aggressiveness of the surgery and to the different efficacy of 
chemotherapy schedules. Among the 246 patients enrolled in table E 1.12 trials 18 
complete responses (CR) and 101 partial responses (PR) were observed for a response 
rate (PR+CR) of 48% (range 40-100%). After induction chemotherapy, 57% of 
tumors received a complete resection. These results appear remarkably improved 
compared to those reported in historical cohorts for stage III and IV patients 
exclusively treated by surgery77. Moreover, a conspicuous number of patients 
received a surgical resection with curative intent after neoadjuvant chemotherapy 
even if they initially had been considered not resectable. 
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Table1.12: Chemotherapy regimes for neoadjuvant therapy of thymic epithelial tumors 
TTP OS Reference Yr Schedule Stage N Pz 
RR 
(%) SD R0 5y 10y 5y 10y 
Kunitoh H78 2010 Dose Dense III 21  13PR  33% 43% Uk Uk 85% Uk 
  Cisplatin   (62%)       
  Doxorubicin          
  Vincristine          
  Etoposide          
Ishikawa Y79 2009 (CAMP) Cisplatin  Iva 67  6PR  14% 29% Uk Uk 81% 70% 
  Doxorubicin   (86%)       
  Methylprednisolone          
Wright CD80 2008 Cisplatin III 7 10 4PR 60% 80% Uk Uk 69% Uk 
  Etoposide IVA 3  (40%)       
  Radiotherapy          
Yokoi K81 2007 (CAMP) Cisplatin  III 4 17 1CR,  7% 12% Uk Uk 81% 81% 
  Doxorubicin IVA 9  12PR       
  Methylprednisolone IVB 4  (93%)       
Lucchi M82 2006 Cisplatin III 20 30 2CR,  27% 77% Uk Uk Uk 82% 
  Epirubicin IVA 10  20PR       
  Etoposide   (73%)       
Jacot W83 2005 Cisplatin III 3 8 6PR  13% Uk Uk Uk 54% Uk 
  Doxorubicin IV 5  (75%)       
  Cyclophosphamide          
Kim ES83 2004 Cisplatin III 11 22 3CR,  23% 76% 77% 77% 95% 80% 
  Doxorubicin IVA 10  14PR       
  Cyclophosphamide IVB 1  (77%)       
  Prednisone          
Berruti A84 1999 (ADOC) Cisplatin III 10 18 1CR  11% 50% Uk Uk Uk Uk 
  Doxorubicin IVA 6  12PR       
  Vincristine   (81%)       
  Cyclophosphamide          
Shin DM85 1998 Cisplatin III 4 12 3CR,  8% 82% Uk Uk 100% Uk 
  Doxorubicin IVA 8  8PR        
  Cyclophosphamide   (92%)       
  Prednisone          
Venuta F77 1997 Cisplatin III 8 25 1CR,  Uk 80% Uk Uk Uk Uk 
  Epirubicin IVA 13  9PR        
  Etoposide   (40%)       
Rea F86 1993 Cisplatin III 16 7CR 0% 31% Uk Uk 66% Uk 
  Doxorubicin IVA  9PR        
  Vincristine   (100%)      
    Cyclophosphamide                   
Yr: year of publication; N Pz: number of patients; RR: response rate; CR: complete 
response; PR: partial response; SD: stable disease; TTP: time to progression at 5 and 
10 -year; OS: overall survival at 5 and 10-year; Uk: unknown, nr: not reached. 
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Targeted therapy 
  Drugs with a designed activity against molecules responsible for the tumor 
growth are available for patients’ treatment. These compounds have shown significant 
activity when appropriately administered in tumors addicted to the targeted 
molecules. For example the use of Imatinib in acute myeloid leukemia inhibits the 
product of BCR-ABL fusion genes inducing long lasting remission in the vast 
majority of patients87. Another example is the use of erlotinib and gefitinib in EGFR 
mutated non-small cell lung cancer able to significantly increase the patient 
survival88,89. However, the same EGFR inhibitors do not shown any or an 
unappreciable activities on those lung cancers without the receptor activating 
mutations. Similarly, many drugs have failed to show a significant effect when given 
outside the right subset of patients.  Drugs, effective for the treatment of other 
neoplastic disease, have been tested in TETs after the failure of one or more 
chemotherapeutic regimens. Drugs targeting EGFR have been tested in TETs. In spite 
of the efficacy depicted in a case report90, gefitinib induced only one partial response 
out of 26 tumors, whereas, none was reported for erlotinib-bevacizumab combination 
(Table G 1.13). Responses to cetuximab, a monoclonal antibody targeting EGFR, 
have been described in anecdotal case reports91,92. Because a case-report has 
described the response to Imatinib of a thymic carcinoma with c-Kit mutation93, the 
drug has been tested in three small phase II trials without any evidence of efficacy 
(Table G 1.13). However, these trials were not selectively designed for tumors 
harboring the sensitizing mutations of c-KIT. As in the meanwhile, some more case-
reports describing thymic carcinomas with KIT mutation sensitive to Imatinib have 
been described94,95, study selectively designed for thymic carcinomas harboring KIT 
mutations have been advocated.  Sorafenib and Sunitinib, two multikinase inhibitors, 
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have induced responses in case reports96-100 and are currently evaluated in phase II 
trials. Because IGF1R as been shown over-expressed in thymic carcinomas and in 
aggressive thymomas101 the specific monoclonal antibody Cixutumumab is under 
evaluation in a phase II clinical trial at NCI. The histone deacetylase inhibitor 
Belinostat has induced 2 partial response and 61% of disease stabilization in a phase 
II trial including pretreated thymoma (25 patients) and thymic carcinoma (16 
patients)102.   
Because TETs, but not normal thymus or thymic hyperplasia, show indium 
labeled octreotide uptake, somatostatin and its analogs have been tested for therapy in 
combination of prednisone103. Among the 52 patients treated 3 experienced a 
complete response, 11 a partial response and 12 a disease stabilization (Table G 1.13). 
Finally, the use of IL-2 and SRC inhibitor did not show any efficacy104,105. 
The efficacy of biologic therapies in TETs is scant, to date. The main 
limitation is the lack of a robust rationale to target a specific molecule, mainly 
because the aberrations driving of TET growth are obscure. The aim and the results of 
this dissertation contribute to clarify the molecular aberration driving the tumor 
phenotype in thymic epithelial tumors and indicate possible new targets suitable for 
therapy.   
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Table 1.13: Targeted therapy trials for palliative treatment of thymic epithelial tumors 
References Year Schedule Line WHO N Pzs RR(%) SD TTP  (m) 
OS 
(m) 
Kurup A106 2005 Gefitinib ≥2 T(19) 26 1PR 54%   
    TC(7)  (4%)    
Bedano PM107 2008 Erlotinib ≥2 T(11) 18 0 61% 4  
  Bevacizumab  T(7)      
Giaccone G108 2009 Imatinib ≥1 T(2) 7 0 2 2  
    TC(5)   0%   
Salter JT109 2008 Imatinib ≥2 TC(11) 11 0 27% 1.5  
             
Palmieri G110 2011 Imatinib ≥2 T(12) 15 0 0 3 nr 
             
Rajan A111 2010 Cixutumumab  ≥2 T(5) 13 0 73%   
          
Giaccone G102 2011 Belinostat ≥2 T(25) 41 2PR 61% 5.8 19.1 
       TC(16)  (5%)    
Loehrer PJ112 2002 Octreotide ≥1 T(31) 36 2CR 17%   
    6PR     
Prednisone  TC(3)  (17%)    
Palmieri G103 2002 Somatostatin ≥2 T(10) 16 1CR 38% 14 15 
  Prednisone  TC(3)  5PR    
    NETC(3)  (38%)    
Gordon MS104 1995 IL2 ≥2 T(14) 14 0 Uk Uk Uk 
             
Line: line of chemotherapy; 1 is first line metastatic disease. WHO: histotype; N Pz: 
number of patients; RR: response rate, CR: complete response; PR: partial response; 
SD: stable disease; TTP: median time to progression in months; OS: median overall 
survival in months; Uk: unknown, nr: not reached. 
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1.8 Paraneoplastic syndromes 
Paraneoplastic syndromes are present in about 40% of thymomas, whereas 
more rarely are associated to thymic carcinomas.  In thymoma paraneoplastic 
syndromes are often autoimmune disorders varying from systemic diseases to organ 
specific syndromes. Myasthenia gravis is the most frequently observed disorder in 
thymomas interesting about 20-30% of patients24. It is related to the tumor 
proliferation and regressions can follow tumor resection or response to radiotherapy 
of chemotherapy.  Other frequently observed syndromes in thymomas are pure red 
cell aplasia and hypogammaglobulinemia24.  
The function of normal thymus is to drive thymocytes through the positive and 
negative selections that follow the TCR rearrangement, in order to generate functional 
lymphocytes (able to recognize the TCR) non reactive to self-antigens (self 
tolerance).  Consequently many authors tend to link the neoplastic degeneration of 
thymic epithelial cells to the high frequency of autoimmune paraneoplastic 
syndromes. In order to avoid maturation of self-reactive T-lymphocytes, the epithelial 
cells of the thymus, especially those of the medulla, presents auto-antigens to the 
thymocytes. Inside the thymic epithelial cells, self-antigens are generated from the 
ectopic expression of tissue–specific autologous genes. Such expression is regulated 
by a transcription factor: the autoimmune regulator gene (AIRE)105. AIRE is 
commonly expressed in normal thymus but not in thymomas and this lack of 
expression may play a crucial role in the pathogenesis of autoimmune diseases by 
favoring the development of self-reactive T-cell clones within the thymus. Despite the 
suggestion that altered AIRE expression provides a fascinating link between 
autoimmunity and malignancy, the etiology of autoimmune disease in thymomas has 
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not been elucidated yet and animal models lacking AIRE genes failed to reproduce 
the pattern of autoimmune disorders observed in thymomas113. 
Thymic carcinomas can be associated with polymyositis, although, these 
autoimmune paraneoplastic syndromes are infrequent. Thymic neuroendocrine 
carcinomas can be associated with endocrine syndromes more commonly ACTH 
mediated Cushing or GH mediated acromegaly24.  
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1.9 Molecular aberrations of thymic epithelial tumors  
The molecular biology of TETs is poorly understood because the availability 
of only a few cell lines, the rarity of the disease, and the lack of specific preclinical 
animal models. A multistep accumulation of genetic and epigenetic aberrations in 
thymic epithelial cells is thought to drive the neoplastic transformation.  
Cytogenetic studies have revealed chromosomal abnormalities in all 
histological subtypes. The recurrent abnormalities found in TETs were only t(15;19) 
translocation and 6p22-p25 deletion 114. The t(15;19)(q13:p13.1) generates the fusion 
gene BRD4-NUT, and tumors with this translocation have been classified as a rare 
subtype of undifferentiated thymic carcinoma according to 2004 WHO classification.  
Comparative genomic hybridization studies have shown low frequency of allelic 
imbalance in type A thymoma115. B3 thymomas present frequent copy number gain of 
1q and loss of 6 and 13q, whereas thymic carcinomas show frequent copy number 
gain of 1q, 17q and 18 and loss of 3p, 6, 16q and 17p115. These aberrations suggest 
close relatedness between B3 thymoma and thymic carcinoma115.  
The role of oncogenes and tumor suppressor genes has been studied in TETs 
with particular emphasis on tyrosine kinase receptors. 70% of thymomas and 53% of 
thymic carcinomas express the EGFR116, which correlates with more advanced stages 
(III-IV) but not with WHO histotypes95,117. EGFR gene amplification, found in 22% 
of thymomas, is responsible for protein over-expression in only a subgroup of 
cases118; B3 thymomas and invasive tumors (stage II-IV) have a higher degree of 
amplification118. Only two L858R and one G863D mutations of EGFR gene have 
been described out of 158 cases studied116. Two KRAS (G12A and G12V) and one 
HRAS (G13V) mutations have been described in a type B2, a thymic carcinoma and a 
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type A thymoma, respectively. However, the frequency of RAS mutations is only 5% 
(3/56) of reported cases95,117,119.  
Stem cell factor receptor (KIT) expression is more frequent in thymic 
carcinoma (73%; 97/132) than in thymomas (2%; 10/423)93,96,98,108,120-128. KIT 
mutations have not been described in thymoma (0/67) and are infrequent in thymic 
carcinoma (5/59). From the observed mutations, the two V560 deletions93,95 and the 
L576P substitution127 are sensitive to imatinib129, D820E to nilotinb, and H697Y to 
sorafenib116.  
.  Expression of BCL2, an anti-apoptotic protein, has been evaluated in TETs. 
BCL2 is expressed in both type A, and the A component of type AB thymomas. 
Thymic carcinomas show high levels of BCL2 expression, whereas only few cases of 
B type thymomas express BCL2130-140.  
 Transgenic mice expressing SV40 large T and small t antigen under L-
pyruvate kinase promoter develop TETs141, implicating the importance of RB and P53 
during TET development. Variable expression of p53 has been reported in TETs 134-
136,139,140,142-152 with p53 being more frequently expressed in invasive thymomas and 
thymic carcinomas. P53 expression is a poor prognostic marker in TETs134,142,144,146 
and inactivating mutations have been described with variable 
frequency95,142,143,145,147,148. In RB pathway, P16INK4 has been evaluated in TET; 
P16INK4, through inhibition of CDK4 and CDK6, prevents RB phosphorylation 
leading to G1-S block. Methylation of P16INK4 promoter has been observed in 3-
13% of TETs, which correlates with p16 down-regulation only in a minority of 
cases147,153. No P16INK4 mutations have been described in TETs, but deletion of the 
gene locus is related to invasive phenotype in rat animal model154.  
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2. Materials and Methods 
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2.1 Patients and tumors 
Patient tumors used for these analyses were collected from four different 
sources:  
1) Slides of FFPE tumors collected from patients enrolled in clinical 
trials at Medical Oncology Branch of National Cancer Institute 
(NCI, Bethesda, MD). Clinical data were collected prospectively 
during such trials. These materials were used for NUT-BRD 
screening. 
2) Frozen tumor samples from patients treated at Medical Oncology 
Branch of NCI (Bethesda, MD) were collected during tumor 
resection and during bioptic procedure for clinical evaluation. 
These tumor samples were used for whole genome sequencing and 
transcriptome/exome sequencing.  
3) Frozen samples collected during tumor resection at Pisa University 
Hospital (Pisa, Italy). These samples were used for 
transcriptome/exome sequencing. 
4) Clinical data and FFPE samples were collected from a series of 132 
consecutive patients who underwent surgery for TET at Humanitas 
Cancer Center (Milan, Italy). These samples were used for array 
CGH, NUT-BRD4 screening and KIT immunohistochemistry and 
sequencing.  
Tumor diagnosis was confirmed by two independent pathologists (H.S.L. and 
M.R.) and histology was classified according to the 2004 WHO classification 24. All 
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patients were staged according to the Masaoka staging system 155. Completeness of 
resection was defined as R0 when complete, R1 when residual disease was 
microscopic and R2 when macroscopic 93. These studies were conducted in agreement 
with the Declaration of Helsinki and were approved by the involved institutional 
ethical review boards (ClinicalTrials.gov ID: NCT00965627; and Pisa University 
Hospital Ethical Committee protocol approval No. 3141). 
 
2.2 Construction of tissue micro array 
FFPE tumor specimens were assessed for quality and adequacy of fixation and 
storage. A tissue microarray (TMA) block containing tissue from 132 thymoma or 
thymic carcinoma cases was generated. In brief, three punches of 0.36 mm2 (0.6 mm 
in diameter) were taken from different intratumoral areas in each tumor sample and 
arranged in the recipient tissue array block. For 21 samples, peritumoral normal tissue 
was also available and included in the TMA. A pathologist (H.S.L.) verified the 
presence of tumor tissue on a hematoxylin-eosin stained TMA slide. Samples were 
considered adequate if tumor occupied one or more cores of three punches.  
 
2.3 Immunohistochemistry 
FFPE tissue slides and/or tissue microarrays were cut at 4 µm, deparaffinized 
with xylene and rehydrated in graded ethanol. Antigen retrieval was performed 
heating the slides at 95 oC for 20 minutes in Target Retrieval Solution (Dako, 
Carpinteria, CA). Endogenous peroxidase blocking solution (EnVision+ System HRP 
(DAB), Dako) was applied on the tissue for 10 minutes followed by incubation in 
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protein-free T20 (TBS) blocking buffer (Thermo Scientific, Rockford, IL) for 1 hour. 
Samples were then incubated with primary antibody 4oC overnight in a humid 
chamber or for KIT 30 min at room temperature. The following reagents were used as 
primary antibodies: anti-NUT rabbit monoclonal antibody C52 (Cell Signaling, 
Danvers, MA), anti-Kit pharmDx™ Polyclonal Rabbit IgG (c-Kit pharmDx™ IHC 
kit, Dako) and anti-p16INK4 mouse monoclonal antibody (BD PharMingen, San 
Diego, CA). After 3 washes with TBST buffer, the slides were incubated for 30 min 
with labeled polymer-HRP as a secondary antibody and then immune reactions were 
visualized with 3’,3’-diaminobenzidine as chromogen (EnVision+ System HRP 
(DAB), Dako). Slides were counterstained with hematoxylin, dehydrated, and 
mounted. Negative control specimens were included with related species antiserum. 
The following positive controls were included: normal testis for anti-NUT antibody, 
mouse normal pancreas for anti-KIT antibody and a xenograft of HELA cell line for 
p16INK4. For NUT immunohistochemistry, results were interpreted as positive if 
nuclear staining was present in more than 50% of cells156. KIT staining was graded as 
negative, no staining; 1+, staining <10% of tumor cells; 2+, staining ≥10% but <50% 
of tumor cells; or 3+, staining ≥50% of tumor cells 123,124. Samples scored 1+ or 
higher were considered positive. P16INK4 results were graded according percentage 
of positive cells and intensity of the staining. Percentage of positive cells was ranked 
0 (0-5%), 1 (6-25%), 2 (26-50%), 3 (51-75%) or 4 (76-100%). Signal intensity (1-3) 
was multiplied by rank of positive cells in order to get a positivity score. P16INK4, 
scores 0-3 were considered negative (G0), 4-6 were G1, 7-9 were G2, and 10-12 were 
G3. 
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2.4 Fluorescence in situ hybridization (FISH) 
Cases positive for NUT antibody staining were processed for FISH analysis as 
described previously157. Dual-color FISH assays evaluating chromosome 19p13.1 
BRD4 and 15q13 NUT break points were performed on 4-µm unstained sections from 
FFPE tissue blocks as previously described157. Probes used for the 19p13.1 BRD4 
break point probes included telomeric tandem bacterial artificial chromosome (BAC) 
clones RP11-319o10 and RP11-681d10 (digoxigenin-labeled, FITC conjugated anti-
digoxigenin-detected, green) and centromeric BAC clones RP11-207i16 and CTD-
3055m5 (biotin-labeled, rhodamine-streptavidin-detected, red). BRD3 break point 
probes included telomeric BAC clone RP11-145e17 (digoxigenin-labeled, FITC 
conjugated anti-digoxigenin, green) and centromeric BAC clone RP11-2243h5 
(biotin-labeled, rhodamine-streptavidin-detected, red).  Probes used for the 15q13 
NUT break point, flanking a 181-kb region, included telomeric BAC clones 1H8 and 
64o3B (digoxigenin-labeled, FITC anti-digoxigenin-detected, green) and centromeric 
clones 1084a12 and 3d4 (biotin-labeled, rhodamine-streptavidin-detected, red).  
 
2.5 DNA extraction and from FFPE material  
Only samples containing >80% cancer cells were selected, as assessed by 
Hematoxylin & Eosin (H&E) stained slides. DNA was extracted using DNeasy kit 
(Qiagen, Inc., Valencia, CA) according to Genomic DNA ULS labeling kit protocol 
(Agilent Technologies, Inc., Palo Alto, CA).  
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2.6 Conventional Sanger sequencing for c-KIT  
Samples were sequenced as previously described158. Briefly, primers were 
designed to cover all the coding sequences of KIT gene. Sequences were amplified by 
PCR using AmpliTaq Gold® PCR Master Mix (Applied Biosystems, Foster City, 
CA). Primers tagged with M13 sequence were used to sequence exon 1 through exon 
20. A total of 40 cycles were performed using Veriti® 96-Well Thermal Cycler 
(Applied Biosystems) at 94 ◦C for 30 s, 60 ◦C for 45 s and 72 ◦C for 45 s. PCR 
products underwent ExoSAP-IT® (USB, Cleveland, OH) purification. The purified 
product was directly sequenced using a BigDye terminator v 3.1 cycle sequencing kit 
(Applied Biosystems) and 3730xl DNA Analyzer (Applied Biosystems). Data was 
analyzed using Mutation Surveyor v 3.23 (SoftGenetics LLC, State College, PA). 
 
2.7 Whole genome sequencing 
15 µg of patient’s tumor and normal DNA were used for whole genome 
sequencing performed using complete genomics platform (Mountain View, CA). The 
methods have been previously described in detail elsewhere159.  Briefly, genomic 
DNA was fragmented and cut by type IIS restriction enzymes; thereafter, directional 
adaptors were inserted to form DNA circles. These DNA circles were replicated by 
synchronized synthesis using Phi29 polymerase (RCR) 8 in order to obtain hundreds 
of tandem copies of genomic fragment sampling the entire genome and named DNA 
nanoballs (DNBs). A silicon substrate with grid-patterned arrays was used to 
adsorbed the DNBs. Using high-accuracy cPAL chemistry, sequencing machines 
were able to read up to 10 bases adjacent to each of the eight anchor insertion sites, 
resulting in a total of 31- to 35-base mate-paired reads (62 to 70 bases per DNB). 
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Data analysis was performed with dedicate in house made pipeline from 
Complete Genomics. The resulting mate-paired reads with a particular gapped 
structure were aligned to USCS hg19 reference genome in a two-stage process. First, 
each end of the reads was aligned independently. Then, the location of the mate pair 
was computed on the basis of the first aligned within the appropriate distance. For the 
mutation calling identification, when a candidate variation was identified, mapped 
reads were assembled into a best-fit, diploid sequence with a custom software suite 
employing both Bayesian and de Bruijn graph techniques.  
 
2.8 Confirmation of candidate mutations  
 Tier 1 mutations identified using whole genome sequencing and the candidate 
junction sequences were confirmed using conventional Sanger sequencing. For SNV 
and INDELS, primers were designed across the mutation site using CLC genomics 
workbench 4 and tested for hairpin and heteroduplex formation using Oliogo 6.8 
Carbon (MBI, Cascade, CO). All designed primers were tagged with M13 sequence. 
PCR Supermix High Fidelity (Invitrogen) was used for PCR amplification that was 
automated on Veriti® 96-Well Thermal Cycler (Applied Biosystems) according to the 
following steps: step 1: 94◦C for 10 minute; step 2: 35 cycles of 94 ◦C for 30 s, 60 ◦C 
for 45 s and 72 ◦C for 45 s; step 3: 72◦C for 7 minutes. PCR products underwent 
ExoSAP-IT® (USB, Cleveland, OH) purification. The purified product was directly 
sequenced using a BigDye terminator v 3.1 cycle sequencing kit (Applied 
Biosystems) and 3730xl DNA Analyzer (Applied Biosystems).  Sequences from 
tumor and normal DNA were evaluated for the presence of the candidate mutation 
using Macvector (MacVector, Cary, NC). 
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2.9 DNA and RNA extraction from frozen material 
 Frozen tumors were imbedded in optimal cutting temperature (OCT) and 8 µm 
slides of the tumors were cut. The slides were colored by Hematoxilin and Eosin and 
a pathologist confirmed the presence of >80% of tumor cells. The selected tumor 
region was macrodissected using a razor blade. Tumor DNA and RNA were extracted 
from the same frozen specimen using All prep RNA/DNA kit (Qiagen, Valencia CA), 
according to vendor instructions. Patients’ blood was collected in 5ml EDTA tubes 
and stored at -80C. Normal DNA was extracted from whole peripheral blood using 
QIAamp DNA blood maxi kit (Qiagen) according to the company protocol. 
 
2.10 Array comparative genomic hybridization  
The labeling procedure was conducted using Genomic DNA ULS labeling kit 
(Agilent), according to the vendor instructions. Twenty samples were hybridized on 
Human Genome CGH Array 105A (Agilent) and the remaining on SurePrint G3 
Human CGH Array 180K (Agilent). The arrays were scanned on a laser-based 
microarray scanner (Agilent), and the data were extracted and normalized using 
Feature Extraction 10.5 (Agilent). Row data were centered to the mode using R script. 
CN profile was inferred using Rank Segmentation algorithm in Nexus 6 
(Biodiscovery Inc., El Segundo, CA, USA). CN call thresholds were defined:  high 
gain +0.7, gain +0.3, loss -0.3 and big loss -0.7. Sex chromosomes were excluded 
from the analysis. Genomic Identification of Significant Targets in Cancer (GISTIC) 
algorithm was applied using the online version on Gene Pattern server 2.0 160.  
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2.11 Exome sequencing 
Exome capture was performed using SureSelect Human All Exon 50Mb Kit 
(Agilent) according vendor instructions. Briefly, libraries from 1µg of genomic DNA 
were generated and then fragmented. DNA fragments were hybridized with 
biotinylated complementary exon sequences. Using magnetic beads exon sequences 
were enriched, then denatured and purified. Captured sequences were fragmented 
using TruSeq DNA Sample Preparation Kit (Illumina) and each fragmented ligated 
with adaptor primers according to vendor instructions. These products were denatured 
and amplified on a Cluster Station (Illumina). One line of Genome Analyzer II (GA-
II, Illumina, San Diego, CA) flow-cell was used to generate 72 pair end sequences.  
 
2.12 Exome sequencing data analysis 
GA-II output files were converted in FASTQ format and assessed for quality of the 
sequencing results using FASTQC software 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). An average of 32.5e6 72 
pair end sequences were obtained from each GA-II line. Sequences were mapped to 
human genome 19 (USCS) using Novoalign (Novocraft, Petaling Jaya, Selangor, 
Malaysia) and deduplicated by Picard (Illumina). Quality recalibration was performed 
using Genome Analysis Tool Kit (GATK, Broad Institute, Cambridge, MA). Single 
nucleotide variation (SNV) and INDELs were called in tumor and normal DNA using 
GATK; for INDELs, re-alignment was performed to reduce false positive mutations. 
Somatic mutations were identified using GATK by subtraction of the SNV and 
INDEL calls from normal DNA to tumor DNA. Somatic mutations were annotated 
using Annovar (http://www.openbioinformatics.org/annovar)  
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Figure 2.1: Exome sequencing procedure. (A) Workflow from genomic DNA to 
sequencing machine. (B) Data analysis pipeline.  
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2.13 RNA quality evaluation  
RNA quality was tested using RNA 6000 nano kit (Agilent) and run on 
Agilent 2100 Bioanalyzer: only samples with a RNA integrity number (RIN) >8 were 
included for transcriptome sequencing. In the Agilent chip a gel electrophoresis of the 
total RNA was performed; the ratio between the florescent peaks corresponding to 
S18 and S28 rRNA bands was adopted to compute the RNA integrity through a 
mathematical algorithm that return a numeric value: being 1 the most degraded profile 
and 10 the most intact. 
 
2.14 Transcriptome sequencing 
Libraries were constructed from 3µg total RNA using TruSeq RNA Sample 
Preparation Kits v2  (Illumina) according to vendor instructions. Briefly, enrichment 
for mRNA was carried out using polyA-tail capture. The RNA was chemically 
fragmented and converted into single strand cDNA using random hexamer priming. 
Then, for each fragment the complementary sequence was generated. An adenosine 
base was added to each end of the fragments and adaptors were ligated with a T base 
overhang on 3’end. These products were denatured and amplified on a Cluster Station 
(Illumina). One line of Hiseq 2000 (Illumina) or GA-II (Illumina) flow-cell was used 
to generate 101 pair end sequences for 2 and 13 samples, respectively. 
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2.15 Transcriptome sequencing data analysis 
GA-II and Hiseq2000 output files were converted in FASTQ format and assessed for 
quality of the sequencing results using FASTQC. Sequences were mapped to human 
genome 19 (USCS) using GSNAP (GVST, http://www.gvst.co.uk/index.htm) and 
deduplicated by Picard (Illumina). Gene expression was estimated using Cufflink 
(University of California Barkley). Bam files were visualized using IGV (Broad 
Institute) to supervised confirmation of the identified mutations.  
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Figure 2.2: Transcriptome sequencing procedure. (A) Workflow from total RNA to 
sequencing machine. (B) Data analysis pipeline.  
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2.16 Cell lines and cell line work  
Thymic carcinoma T1889 and B1 thymoma T1682 cell lines were kindly 
provided by Dr. Marco Breinig 161. TY-82 thymic carcinoma cell line was purchased 
from Japan Health Science Foundation (Tokyo) whereas HELA, HEK-293, H157, 
NCI-H146 and NCI-H82 were from ATCC. All cell lines were cultured in RPMI 
1640 containing 200 mM L-Glutamine (Invitrogen, Grand Island, NY), 50 U/mL 
penicillin, 50 U/mL streptomycin (Invitrogen) and 10% heat-inactivated calf serum 
(Invitrogen) and grown in a 37 oC incubator with humidified 5% CO2 atmosphere. 
Protein extraction, western blot and immunoprecipitation were performed as 
previously described 162,163. Anti-BCL2 antibody was purchased from DAKO 
(Carpinteria, CA), anti-MCL1 and anti-p16INK from BD PharMingen and all the 
remaining antibodies were from Cell Signaling. Activity of ABT263 and Gx15-070 
(Selleck Chemicals, Houston, TX) was tested using a proliferation assay (CellTiter 96 
Non-Radioactive Cell Proliferation Assay, Promega), a vitality assay (CytoTox 96 
Non-Radioactive Cytotoxicity Assay, Promega) and a membrane permeability assay 
using TOPRO3 (Invitrogen) staining for flow cytometry (FACScalibur and Cellquest, 
BD), because Gx15-070 generates auto-fluorescence that interferes with propidium 
iodide and 7AAD. Caspase-3 activity was calculated using a colorimetric Caspase-3 
Activity Detection Kit (Millipore, Billerica, MA).  
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2.17 ShRNA, siRNA and transfection experiments 
BECN1 shRNAs (1: V2HS_23694 and 2: V2HS_241693) and RIPK1 
shRNAs (1: V2HS_17422 and 2: V2HS_241668) were purchased from Open-
Biosystems (Thermo Scientific, Huntsville, AL) and subcloned into pMSCV-PM-
pheS retroviral expression vector (Clontech, Mountain View, CA). High titer shRNA 
viral particles were produced in HEK-293T packaging cells and infection of TET cell 
lines was carried out in the presence of 4 µg/ml polybrene (Millipore, Billerica, MA). 
 Anti-apoptotic BCL2 family member ON-TARGETplus siRNA pools and 
ON-TARGETplus Set of 4 siRNAs were purchased from Dharmacon (Lafayette, 
CO). Transfection was performed using PepMute siRNA Transfection reagent 
(SignaGen Laboratories, Rockville, MD) and 10 nM of each siRNA.  
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2.18 Statistical analysis 
Clinical and biological characteristics were compared using the Fisher's exact 
test, χ2 test, Student’s T-test or One-way ANOVA with Dunn test for post-hoc 
comparisons, when appropriate. P-values were considered significant at the < 0.05 
level (two tailed). Survival curves were generated using the Kaplan-Meier method 
and differences tested by Log-Rank test. Multivariate analyses were performed using 
Cox proportional hazard model. Disease-Related Survival (DRS) was calculated from 
the date of surgery to the date of death; patients dead for causes other than tumor 
progression were censored.  Time to progression (TTP) was calculated from date of 
surgery to relapse or progression; patients dead without any evidence of tumor 
progression were censored. For patients who do not undergo surgical resection TTP 
and DRS were calculated from tumor biopsy. All tests were performed using the 
SPSS version 17 (SPSS, Inc., Chicago, IL). Synergism of drug combination was 
calculated using CalcuSyn 2.1 (Biosoft, Cambridge, UK). 
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3. Results 
3.1 Overview and strategy of the performed experiments 
 Genomic aberrations have been studied in TETs by karyotype analysis and 
conventional CGH studies on a limited number of cases. Karyotype studies revealed 
an heterogeneous status of aberrations. Among these abnormalities only the 
translocation t(15;19) and deletion of part of the short arm of chromosome 6 were 
recurrent. Deletion of chromosome 6p was confirmed by conventional CGH in 
thymomas and thymic carcinomas115. Chromosome 6p deletion is going to be 
evaluated by array CGH in the following sections. KIT mutations have been described 
in thymic carcinoma and have been related with response to tyrosine kinase inhibitors 
in case-report studies164. 
NUT-BRD4 translocation and the presence of KIT mutations were evaluated 
because, even if they have been reported in TETs, their incidence was not know. 
Given the low frequency observed for both mutations, a genome wide screening 
approach was chose to identify those genomic aberrations driving the TET growth. 
We applied whole genome sequencing to a B3 thymoma cases and whole exome 
sequencing to 3 thymomas and 2 thymic carcinomas. In these tumors, among a 
relevant heterogeneity of the feature observed, the copy number (CN) aberrations 
identified by CGH pointed CDKN2A and BCL2 as relevant genes for TET biology. 
Being the CN aberrations the most common way of deregulation of these genes, CGH 
analysis was extended to a larger series of tumors and the function of these genes was 
studied in TET cell line models.   
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3.2 NUT-BRD4 fusion gene in thymic epithelial tumors 
The translocation t(15;19) originate a fusion proteins BRD4-NUT, resulting in 
the ectopic expression of NUT protein. NUT rearrangement has been found in ~10% 
of midline carcinomas165 in children and young adults. Approximately two thirds of 
NUT rearrangements on 15q14 in NUT midline carcinomas (NMCs) occur in a 
balanced translocation with BRD4 (bromodomain containing protein 4) gene on 
19p13.1 creating BRD4-NUT fusion protein, and the remaining one third (NUT 
fusion variants) either with BRD3 on 9q34 or with some unknown partners. NUT, a 
testis specific protein, is highly expressed in normal testis and does not contain any 
known functional domain166, whereas BRD4 is ubiquitously expressed in somatic 
cells166,167. The fusion proteins retain both bromodomains of BRDs and almost the 
entirety of the NUT coding sequence168. BRD3 and BRD4 belong to a specific family 
of transcription/chromatin regulators known as BET. They are double bromodomain-
containing proteins, which preferentially associate with acetylated histones169,170. 
BRD4 binds mitotic chromosomes and may stimulate RNA polymerase II dependent 
transcriptional elongation post mitotic silencing171-173, whereas the function of BRD3 
is less characterized. Although the molecular mechanisms of BRD-NUT fusions in 
NMC development is unclear, knockdown of the fusion proteins in NMC cells 
induces cell cycle arrest and squamous differentiation168. There are only a few 
sporadic reports of t(15:19) translocations in thymic carcinomas174-177.  
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Clinical Features of studied thymic epithelial tumors 
The 2004 WHO tumor classification system denotes this subgroup of thymic 
carcinomas as t(15;19) carcinomas. A total of 148 TETs were included in this study, 
111 of which were thymomas and 37 thymic carcinomas. The median age of our TET 
cases was 55 years ranging from 20 to 87 years. The median survival rate of the TETs 
was 192 months (95% CI 65.3 – 318.7). Twenty-one of the 37 thymic carcinoma 
patients (57%) were diagnosed as stage IV carcinomas according to the Masaoka 
staging system, 16 of which were in stage IVB with metastatic tumors (Table 3.1).  
The median age of our thymic carcinoma series (n = 37) was 54 years ranging from 
28 to 72 years. The median survival was 48 months (95% CI 30.6-65.4; Figure 3.1A).  
Histologically, most of the thymic carcinomas were squamous (n=17) or 
undifferentiated subtypes (n = 8). In agreement with previous reports 178,179, 
immunohistochemistry analysis of p63, one of the two p53 homologues, revealed that 
p63 was positive in most  (17/19) of the thymic carcinomas studied (Table 3.1). 
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Table 3.1. Case characteristics of thymic carcinomas 
Case  Age Sex Stage* Histology P63 IHC Survival (months) 
1 56 F IVB Squamous cell + 14 
2 33 M IVB Non-papillary adenocarcinoma (mucinous) + 41 
3 65 M I Squamous cell + 146+ 
4 49 M IIA Mucoepidermoid ND 67+ 
5 53 M IVB Squamous cell + 75+ 
6 32 M IIIB Neuroendocrine - 103+ 
7 64 M IIIA Squamous cell + 50+ 
8 72 F I Squamous cell + 125+ 
9 64 M IIIA Squamous cell ND 28+ 
10 55 M IIB Neuroendocrine ND 71 
11 67 M IIIA Non-papillary adenocarcinoma (mucinous) + 59+ 
12 61 M IVB Undifferentiated + 1 
13 61 M IVA Undifferentiated + 32+ 
14 63 M UK Squamous cell ND 48 
15 69 M IVA Squamous cell ND 51 
16 64 F IVA Undifferentiated ND 34 
17 39 M IVB Basaloid - 9 
18 59 M IVB Undifferentiated ND 23 
19 28 M IVA Neuroendocrine (large cell) ND 56 
20 59 M UK Undifferentiated + 12 
21 53 F IVB Undifferentiated + 20 
22 37 M IVB Squamous cell ND 20+ 
23 38 F IIIB Squamous cell ND 19 
24 32 F IVB Squamous cell + 8 
25 52 F IVB Squamous cell + 18 
26 61 M IIIB Undifferentiated ND 20 
27 54 M IVB Squamous cell + 36 
28 47 M IVB Neuroendocrine (large cell) ND 61 
29 46 M IVB Squamous cell + 30 
30 40 F IVB Undifferentiated ND 29 
31 30 M IVB Basaloid + 26 
32 55 M IVB Neuroendocrine ND 40 
33 44 F IIIA Squamous cell + 49 
34 31 F I Neuroendocrine (atypical carcinoid) ND 55 
35 45 M IVA Squamous cell ND 61 
36 67 F IIIB Lymphoepithelioma-like ND 62 
37 61 F IIIA Squamous cell ND 12+ 
    *Stages were determined according to the Masaoka staging system; IHC, 
immunohistochemistry; UK, unknown; ND, not done. 
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The overall survival of thymic carcinomas (10-year OS rate 20%) was poorer than 
thymomas (10-year rate 72%; p<0.001) in our series including 37 thymic carcinomas and 111 
thymomas. It is interesting to note that among the 37 thymic carcinomas analyzed in this 
study overall survivals were significantly poorer in undifferentiated (median survival: 23 
months; 95%CI 14.3 – 31.8) than differentiated carcinomas (median survival: 55 months; 
95%CI 44.5 – 65.5; Figure 3.1B) and in metastatic (median survival: 26 months; 95%CI 15.2 
– 36.8) than non-metastatic tumors (median survival: 56 months; 95%CI 45.3 – 66.7; Figure 
3.1B and C; LogRank p = 0.001 and p = 0.002 respectively).  
 
Figure 3.1: Survival analysis of thymic carcinoma patients. (A) Overall survival curve of 
thymic carcinoma patients (median: 48 months). (B) Overall survival by differentiation 
status. (C) Overall survival by metastasis status. Survival curves were generated using the 
Kaplan-Meier method. MTS: metastasis. 
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NUT rearrangement in thymic carcinomas is uncommon 
Clinicopathological features of previously reported thymic carcinomas with t(15;19) resulting 
in constitutive BRD4-NUT fusion gene expression are summarized in Table 3.2. They appear 
to be undifferentiated and very aggressive tumors with remarkably poor survival. Taking 
advantage from the specificity and accuracy of NUT antibody in identifying NMCs156, NUT 
expression was screened  in 148 TETs by immunohistochemistry. All of the 148 cases were 
found negative for NUT expression with the exception of one thymic carcinoma that 
exhibited speckled nuclear NUT staining (Figure 3.2 A), a typical NUT staining pattern 
found in other NMCs156. To determine if the NUT-positive tumor carries BRD3- or BRD4-
NUT rearrangement, we performed FISH analysis using split-apart NUT, BRD3 and BRD4 
probes respectively as described previously157. The tumor showed an evident NUT but not 
BRD3 or BRD4 rearrangement (Figure 3.2 B), indicating this is a variant NUT rearrangement 
tumor. The patient was a 30 year-old male diagnosed with stage IVB thymic basaloid 
carcinoma according to the Masaoka staging system and WHO histology classification. 
Computed tomography of the chest and abdomen showed bulky mediastinal mass suggestive 
of thymic origin, and enlarged left supraclavicular  and para-aortic lymph nodes (Figure 3.2 
C).  
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Table 3.2: Features of reported thymic/mediastinal carcinomas with t(15:19) 
 Cases 
Features  
1 2 3 4 5 
Age/Sex 22/F 11/F 5/M 15/M 30/M 
Tumor Origin anterior 
mediastinum, 
thymus 
intrathorax, thymus, 
lung, nonseminomtous 
germ cell, mediastinal 
teratocarcinoma 
disseminated anterior 
mediastinum, 
thymus 
anterior mediastinum, 
thymus 
mediastinum, 
thymus 
Pleural effusion yes - yes yes - 
Metastasis lung, bone, bone bone bone lymphnode, 
bone 
Survival (mo) 3.5 4.5 1.5 6 26 
Pathology* undiff. ca undiff. ca undiff. ca poorly diff. squamous ca basaloid ca 
EMA + ? + +  
CK +/-† + + + + 
CEA - + + +  
CD5     + 
NUT + + not done + + 
NUT partner BRD4166 BRD4168 BRD4|| BRD4168 UK 
Karyotype¶ t(15;19)(q15;p13) t(15;19)(p12;q13) t(15:19)(q12;p13.1) t(11;15;19)(p15;q12;p13.3) ND 
References Kubonishi et al174,175 Kees et al180 Lee et al177 Toresky et al176 present 
*Cases were also diagnosed as: malignant lymphoma, diffused large cell type (case 1); lung 
undifferentiated carcinoma (case 2); mediastinal carcinoma of mucoepidermoid type (case 3). 
†Keratinizing foci within tumors were positive, but the cell line (Ty82) derived from the tumor was 
negative for cytokeratin. 
|| Presumed BRD4-NUT rearrangement based on cytogenetics.  
¶Karyotypes were quoted from the original publications.                                                                                  
EMA, epithelial membrane antigen; CK, cytokeratin; CEA, carcinoembryonic antigen; CD5, 
cluster of differentiation 5; undiff, undifferentiated; diff, differentiated; ca, carcinoma; ND, not 
done; UK, unknown. 
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Figure 3.2: NUT in thymic carcinoma. (A) NUT immunohistochemistry. NUT-positive (left) 
and –negative (right) thymic carcinomas. Note that in the thymic carcinoma with NUT 
rearrangement the speckled NUT expression was mainly restricted in the undifferentiated cell 
nuclei and much less NUT was in the differentiated squamous cell area. (B) NUT gene 
rearrangement in a thymic carcinoma. Dual-color split-apart FISH was performed with 
probes flanking 5’ centromeric (red) and 3’ telomeric (green) of NUT, BRD3, and BRD4 
respectively as described previously. Arrows (left panel)  marked split-apart NUT signals 
(red/green signals were split apart due to NUT rearrangement), whereas no BRD3 (not 
shown) or BRD4 split-apart signal (right panel) was detected in the same tumor sample 
indicating that the NUT rearrangement did not  involve BRD3/4. (C) Computed tomography 
of the thymic carcinoma patient with NUT rearrangement: left supraclavicular lymph nodes, 
primary bulky mediastinal mass, and para-aortic lymph nodes. 
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Core needle biopsy of the primary mediastinal mass at the time of diagnosis showed a 
squamous cell carcinoma with a basaloid component (Figure 3.3 A). Immunostaining was 
positive for p63, CD5, cytokeratin AE1/AE3 (Figure 3.3B-D) and c-KIT (data not shown), 
confirming the diagnosis of thymic carcinoma. Metastases were found in lymph nodes and 
bones at the time of diagnosis. Later in the disease course, fine needle aspirate of a 
supraclavicular lymph node showed atypical cells in a necrotic background suspicious for a 
metastasis from a thymic carcinoma. The patient underwent thoracocentesis to relieve a left-
sided pleural effusion following which he received two cycles of multi-drug chemotherapy 
consisting of cisplatin, doxorubicin and cyclophosphamide. A restaging CT scan did not 
show any significant changes. Two and a half months later the patient presented to the 
National Cancer Institute where he first underwent thoracocentesis. The patient was enrolled 
onto the ongoing clinical trial with anti-insulin-like growth factor-1 receptor antibody, 
cixutumumab and received three cycles of treatment every three weeks following which he 
was taken off treatment due to disease progression. He then received a course of palliative 
radiation therapy to control painful tumor deposits in the left chest cavity and supraclavicular 
fossa, following which he opted to receive supportive care only. The patient passed away 2 
months later, which was 26 months after initial onset of symptoms. Given that the NUT 
immunostaining is highly accurate in NUT rearrangement prediction and NMC identification 
156, and that only one of the 148 TETs was found positive for NUT expression and 
rearrangement, we conclude that NUT rearrangement is rare in TETs. 
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Figure 3.3: Thymic carcinoma with a basaloid component.  (A)  Mediastinal tumor cells with 
NUT rearrangement infiltrate in the fibrous stroma. Keratinization is seen  (H&E; x20). (B) 
Keratin immunohistochemistry.  Tumor cells are strongly and uniformly positive (AE1/AE3 
immunostain; x20). (C) p63 shows positive staining mainly in the basaloid component (p63; 
x20). (D) Epithelial cells also express CD5 (CD5; x20). 
  ‐ 89 ‐ 
3.2 Expression and mutational status of c-Kit in thymic epithelial tumors 
c-Kit is a type III cytokine receptor expressed on the membrane of hematopoietic 
stem cells, mast cells, melanocytes and interstitial cells of Cajal181. Stem cell factor binds to 
c-Kit inducing homodimerization of the receptor and phosphorylation of downstream 
intracellular molecules, regulating cell proliferation, differentiation, adhesion and 
apoptosis182. Overexpression of c-KIT is observed in a spectrum of human malignancies, 
primarily gastrointestinal stromal tumors (GISTs), chronic myeloid leukemias (CML), mast 
cell neoplasms, melanomas, and seminomas183. c-KIT mutations have also been described in 
several of these tumors182,184. In GISTs the most common mutations affect exons 11, 9, 13 
and 17182 and the site of mutation has prognostic implications in this disease. Responsiveness 
of GISTs to treatment with the kinase inhibitor Imatinib depends largely on the exonic 
location of the c-KIT mutation182. Higher objective response rates to Imatinib have been 
described in patients with mutations of exon 11 compared to patients with wild type receptor 
or with mutations of exon 9185. Mutations have been also described in patients with negative 
c-Kit expression, evaluated by immunohistochemistry (IHC)186. Durable responses to 
Imatinib treatment were observed in GIST patients with a very low expression of c-Kit but 
showing exon 11 mutations187. 
In TETs, c-Kit expression has been reported between 50-88% in thymic carcinoma 
but it is rare in thymomas (0-5%)95,121,123,124,183. In thymic carcinoma, few mutations have 
been described in the literature93,95,124,183.  Recently Girard et al. reported 2 c-Kit mutations, 
out of 7 thymic carcinomas analyzed95. One of these mutations (H697Y) was novel and found 
in exon 14, a region not sequenced in previous studies. 
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In 2004 Stroebel et al. reported a case of poorly differentiated epidermoid carcinoma 
with V560del Kit mutation who responded to Imatinib93. In 2009 another case of thymic 
carcinoma with D820E Kit mutation was reported that responded to Sorafenib, a multitarget 
tyrosine kinase inhibitor, with weak c-Kit inhibitory activity96,188. Three small phase II trials 
have been performed with Imatinib in patients with no evidence of response108-110.  
 
c-KIT immunohistochemistry 
A tissue microarray was generated from a series of 132 thyic epitelial tumors. This 
series is going to be described in detail in chapter 3.5. Examples of positive and negative 
samples are shown in Figure 3.4 A and B. There was no c-Kit expression by IHC in the 
normal residual thymus of 9 evaluable patients. Ten (8.3%) out of 120 evaluable samples 
were positive for c-KIT expression. This included 6 of 13 thymic carcinomas tested (46%) 
and 4 of 107 thymomas (4%). c-KIT expression was significantly more frequent in thymic 
carcinomas than in thymomas (Fisher exact test p<0.0001). There was no difference in c-KIT 
expression between early vs advanced stages, level of completeness of resection, and primary 
vs relapsed tumors. However, c-KIT positive samples were all found in primary (98 cases) 
and none in relapsed tumors (22 cases). All patients with tumors showing c-Kit expression 
were older than the median age of 55 years (Fisher exact test p=0.001). c-KIT expression was 
associated with a worse DRS (Log Rank p=0.028; Breslow p=0.002). The 10-years DRS was 
90% for c-KIT negative and 71% for c-KIT positive patients (Figure 3.4 C). A statistically 
significant worse TTP (TTP) was observed using the Breslow test (p=0.001) but not using the 
LogRank test (p=0.061). The 10-year TTP was 70% for c-KIT negative patients and 50% for 
c-KIT positive patients (Figure 3.4 D). 
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Patients with thymic carcinoma showed a statistically significant worse DRS than 
thymomas (Log-Rank p=0.002; Breslow p=0.003). Median survival was not reached for both 
groups. The 10-year DRS was 60% for thymic carcinomas and 91% for thymomas (Figure 
3.4 E). Also the TTP was significantly worse for thymic carcinomas (Log-Rank p=0.021; 
Breslow p=0.002). The estimated median TTP was 69.4 months for thymic carcinoma 
(95%CI 0-142.7) and 147 months for thymomas (95%CI 121.7-172.4). The 10 year TTP was 
43% for thymic carcinoma and 72% for thymomas (Figure 3.4 F). By multivariate analysis, 
c-KIT expression was neither an independent prognostic factors for DRS (p=0.67 and 0.22, 
respectively) nor for TTP (p= 0.79 and p=0.23, respectively). However, the small number of 
cases limts the possibility to draw definitive conclusions on the prognostic value of KIT 
expression expecially because the multivariate analysis was not significat, being KIT usually 
positive in thymic carcinomas.  
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Figure 3.4: KIT staining results (A) Membrane c-Kit positive staining 40x original 
magnification; (B) c-Kit negative staining 40x original magnification; Kaplan Meier plot for 
(C) disease-related survival of patients positive or negative for c-Kit expression; (D) time to 
progression related to c-Kit expression; (E) disease-related survival of thymoma and thymic 
carcinoma patients; (F) time to progression of thymoma and thymic carcinoma patients. 
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Sequencing analysis of KIT 
We sequenced all the exons of KIT in 8 thymic carcinomas and 5 thymomas from FFPE 
samples with a success rate of 77.5%. Histological characteristics of the  tumors that 
underwent sequencing are reported in table 3.3. We did not detect mutations in any of the 
tumor samples and in the T1889 thymic carcinoma cell line, previously reported to be 
negative for c-Kit expression161. We observed the previously reported single nucleotide 
polymorphism (SNP) corresponding to M541L in one type A thymoma and in one thymic 
carcinoma189. 
Table 3.4 summarizes the studies that have investigated c-Kit mutations in TETs. 
Only a few c-Kit mutations have been reported and those were exclusively detected in thymic 
carcinomas. No KIT mutations were reported in thymomas among 88 cases sequenced. In 
thymic carcinoma only 5 mutations have been described among the 59 cases studied (9%). 
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Table 3.3: Thymic carcinoma and thymoma histology, mutation and c-Kit 
immunohistochemistry 
Sample Histotype c-Kit IHC KIT mutation 
I-Thy 1 Squamous cell carcinoma +3 No 
I-Thy 2 Mucinous adenocarcinoma  0 No 
I-Thy 3 Squamous cell carcinoma +2 - 
I-Thy 4 Mucoepidermoid carcinoma 0 No 
I-Thy 5 Squamous cell carcinoma 0 No 
I-Thy 6 Neuroendocrine carcinoma 0 - 
I-Thy 7 Squamous cell carcinoma +1 - 
I-Thy 8 Squamous cell carcinoma +3 No 
I-Thy 9 Squamous cell carcinoma +2 No 
I-Thy 10 Neuroendocrine carcinoma 0 No 
I-Thy 11 Mucinous adenocarcinoma  +3 No 
I-Thy 12 Undifferentiated carcinoma 0 - 
I-Thy 13 Undifferentiated carcinoma 0 - 
I-Thy14 Thymoma type A +1 No 
I-Thy 15 Thymoma type B3 0 No 
I-Thy 16 Thymoma type AB +1 No 
I-Thy 17 Thymoma type A +1 No 
I-Thy 18 Thymoma type B3 0 No 
T-1889 Undifferentiated carcinoma cell line 0161 No 
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Table 3.4: Summary of published reports of c-Kit expression and mutation in TEMs  
 
Reports Samples IHC - IHC + Mutation - 
Mutation 
+ 
Described 
mutations 
Retrospective studies       
        
 Henley 2004121 Thymoma 19 1 (5%)    
  TC 4 11 (73%)    
        
 Pan 2004122 Thymoma 110 0    
  TC 3 19 (86%) 21   
        
 Nakagaua 2005123 Thymoma 48 2 (4%)    
  TC 4 16 (80%)    
        
 Tsuchida 2008124 Thymoma 20 0    
  TC 6 11 (65%) 9   
        
 Yoh 2008127 Thymoma 24 0 22   
  TC 2 15 (88%) 10 1 L576P 
        
 Girard 200995 Thymoma 33 0 38   
  TC 3 3 (50%) 5 2 V560del  
       H697Y 
Phase II trial       
        
 Salter 2008190 TC 2 9    
        
 Giaccone 2009191 Thymoma 2 0 2   
  TC 1 1 1   
        
Case reports       
        
 Stroebel 200493 TC  1  1 V560del 
        
 Bisagni 200996 TC  1  1 D820E 
        
 Li 200998 TC  1    
        
  Vasamiliette 2009192 TC  1    
        
This series       
  Thymoma 103 4 (4%) 5   
  TC 7 6 (46%) 8   
        
Total        
  Thymoma 359 7 (2%) 67 0  
  TC 32 95 (75%) 54 5  
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3.3 Complete genome sequencing of a B3 thymoma 
Patient’s clinical history 
In April 2007, a 55 years old Caucasian female presented whit shortness of breath and 
fatigue. A computed tomography (CT) revealed a left side anterior mediastinal mass of 
12.3x7.9cm infiltrating the pericardium, the diaphragm and the left lung but without 
evidences of distant metastases. The patient underwent a mediastinoscopy with curative 
intent but during the procedure the tumor was judged unresectable and a biopsy was 
performed. The pathological diagnosis was B3 thymoma in stage IIIA.  She did not show any 
paraneoplastic or immunological syndrome possibly associated with the disease. The patient 
received 6 cycles of chemotherapy according to the ADOC schema (Cisplatin, Doxorubicin, 
Vincristine and Cyclophosphamide) reaching a minor response. After 6 months, the tumor 
progressed and the patient received 3 cycles of ifosfamide obtaining a disease progression. 
Thereafter, she received prednisone therapy for 5 months up to a minor response of disease. 
In April 2009, she has been referred to NCI (Bethesda, MD), where the restaging of the 
tumor did not showed any evidence of progressive disease nor distant metastases. The patient 
received an extended resection of the tumor, part of the diaphragm, part of the pericardium, 
part of left chest wall and a left pneumonectomy without evidence of macroscopic residual 
disease. The pathology report confirmed the diagnoses of B3 thymoma infiltrating the 
pericardium the lung and the diaphragm but the absence of infiltrating margins. The patient 
refused adjuvant radiation therapy and did not present any evidence of disease for 26 months. 
Then the patient developed fatigue, dyspnea (New York Heart Association grade 3) and chest 
pain associated with exertion and relieved by rest. The cardiologic follow up demonstrated 
absences of coronary disease, a left ventricle ejection fraction of 55% and the presence of 
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pericardial nodules and effusion. The CT demonstrated local relapse in the site of left lung 
ileum and in the cardiac root region with encasement of the pulmonary artery. The patient 
was treated by radiation therapy, utilizing IMRT modality with 6MV photons to a total dose 
of by 6300 cGy in 180 cGy fractions, obtaining relieve of symptoms. Currently, after 10 
months the patient is still asymptomatic without any further evidence of disease progression.  
 
 
Figure 3.5: KSA tumor features. Panel A depicts the CT scan results performed before the 
surgical resection showing the cardiac root, the tumor occupying large part of the left 
hemithorax and invading the chest wall.  (B) Summary of array CGH results for autosomal 
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chromosomes: in red are reported regions of CN gain and in blue of CN loss. Panel C and D 
report histology results for the resected sample showing 10x and 40x magnification, 
respectively. The tumor is organized into large nets of epithelial cells separated by fibrous 
bans; to be note the round-polygonal shape of the thymic epithelial cells in almost complete 
absence of lymphocytes. Scale-bar is 100µm in C and 50µm in D.  
 
Preparation and validation of tumor material 
Part of the tumor resected at NCI was snap frozen in liquid nitrogen and preserved at -
180oC. The frozen tumor was imbedded in optimal cutting temperature (OCT) and 8µm 
slides of the tumors were cut. The slides were colored by Hematoxylin and Eosin and a 
pathologist confirmed the presence of >80% of tumor cells and histological features 
compatible with the diagnosis of B3 thymoma. Tumor DNA and RNA were extracted from 
the same frozen specimen using All prep RNA/DNA kit (Qiagen, Valencia CA). Array CGH 
was performed using tumor DNA and normal human male DNA from Promega (Madison, 
WI) as reference. The array CGH analysis revealed copy number (CN) gain of chromosome 
1q, 5 and 7 and CN loss of chromosome 3p, 6, 13 and part of chromosome 11q in the 
autosomal chromosomes. These data are compatible with those reported for B3 thymomas by 
Zetel A, et al. by conventional CGH115 and by Girard N, et al. by array CGH95, confirming 
the presence of a large proportion of tumor cells in the sample. Patient’s normal DNA was 
extracted from 5 ml of whole peripheral blood using QIAamp DNA blood maxi kit (Qiagen).  
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Whole genome sequencing results 
High throughput sequencing generated 222.2 and 234.53 Gb of mapped sequences 
against reference genome for tumor and normal DNA, respectively. More than 95% of the 
genome was fully covered in tumor and normal DNA being able to call variation in each 
allele. A total of 3,096,049 of single nucleotide variations (SNVs) were observed in tumor 
DNA whereas a total of 3,314,611 in the normal DNA. The presence of extended regions of 
CN loss in tumor DNA could explain the higher number of SNV observed in normal than in 
tumor DNA. Similarly an increased number of INDEL was observed in normal DNA Table 
3.5. 
 
 
 
 
 
 
 
Table 3.5: summary of whole genome sequencing results 
 Tumor Normal 
Mapped sequence yield (Gb) 222.02 234.53 
Fully called genome fraction 95.3% 96.4% 
SNV total count 3,096,049 3,314,611 
Novel SNV 133,662 145,929 
SNV Transitions/transversions 2.14591 2.14218 
INS total count 158,681 173,448 
DEL total count 174,697 192,178 
INDEL total count 333,378 365,626 
Insertion/deletions ratio 90.8% 90.3% 
Novel INDEL 67,163 74,562 
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Complete genomics analysis (CGA) tool was adopted to call tumor specific variations 
(somatic). 6530 candidate somatic SNVs were observed together with 2776 insertions, 1600 
deletions and 1570 substitutions. The somatic SNVs and INDELs were disperse in the 
genome and have been organized in 4 groups: 
Tier 1: mutations affecting exons with the following characteristics: (n=47)  
a) Not synonymous (the nucleotide change results in a triplet coding for a 
different amino-acid.   
b) SNV not previously described in dbSNP135 except those mutations 
concomitantly described in COSMIC database. 
Tier 2: mutations affecting splicing sites (n=6) and RNA genes (n=24) or highly conserved 
regions in non-repeat masked regions in USCS (n=153; degree of conservation was 
calculated using phastCons44way tables: phastCons is an algorithm that generates similarity 
scores from the multiple alignments of 44 vertebrate genomes to the human genome. 
PhastCons score >500 discriminates highly conserved regions193).  
Tier 3: mutations affecting not repeated regions (n=1881) 
Tier 4: all other mutations (n=10365) 
The 47 candidate mutations from tier 1 were validated using Sanger sequencing; 8 of them 
were confirmed (table 3.6), the WDR70 G1823A mutation was identified in tumor and 
normal DNA and consequently classified as germ line variation. An higher confirmation rate 
(25%) was observed for SNVs than for INDELs (4%) being confirmed only that interesting 
BCOR locus.  
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Table 3.6: confirmed INDELS and SNVs 
Gene symbol Genomic location NCBI reference sequence 
Nucleotide 
modification 
Amino acid 
change 
VN1R5 chr1:247419950 NM_173858 C577T R193W 
PHF15 chr5:133914340 NM_015288 T1706A L569Q 
PION chr7:76978720 NM_017439 A1493 E498G 
PPP1R3A chr7:113517959 NM_002711 G3188C G1063A 
SFXN3 chr10:102795325 NM_030971 T245C F82S 
PCNXL3 chr11:65385813 NM_032223 C980A P327Q 
SRGAP1 chr12:64491096 NM_020762 G1754A R585H 
BCOR chrX:39930263 NM_001123385 3201_3202insGA Frame-shift 
Genomic position is related to hg19; nucleotide modifications and amino acid change 
positions are related to the specified NCBI Reference sequence. 
 
 Junction sequences 
Junction sequences are those resulting from the joint of two sequences normally not 
adjacent or in the same orientation in the reference genome. These sequences can originate 
from either the same or a different chromosome. Thus, junction sequence can be the result of 
structural variations (SV) such as deletions, duplication, inversions, and translocations 
(Figure 3.6).  
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Figure 3.6: schematically summary junction sequences consequence of frequent DNA 
rearrangements.  
Using junctiondiff (CGAtool) a list of 97 predicted tumor specific junctions was 
generated by subtracting normal from tumors junctions. Fillers were applied excluding SVs 
not supported by a sufficient number of discordant paired-ends (pair count < 20) and with 
small span size (span< 5kb). Six variations met these criteria but 3 of them have been also 
described in a dataset of structural variation generated by sequencing 52 genomes of normal 
persons (disease free) using complete genomic platform, thus these shared junction sequence 
highlight regions of the genome that are difficult to call or are heterogeneous within 
individuals or have been not mapped in the reference genome yet. Thus, only 3 tumor 
specific junction sequences were robust candidates (Table 3.7) 
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Table 3.7: candidate structural variation (junction sequences) 
Variation Left position Left strand Right position Right strand 
1 chr11:49883579 - chrM:16083 + 
2 chr11:86017394 + chrX:123645300 + 
3 chr1:158725872 + chr2:148952671 - 
 
  
Primers for left and right position were designed and PCR performed on the tumor and 
normal patient DNA in order to detect the presence of the aberration and evaluate its tumor 
specificity. Moreover, an unrelated reference male genome DNA (Promega) was introduced 
as negative control. Figure 3.7 reports PCR results; the candidate variation 1 was present in 
patient’s tumor, normal and unrelated normal DNA and probably it is related to a normal 
genomic sequence not already mapped in the current version of the human genome (hg19). 
The variation 2 was present only in the tumor DNA, thus it was considered validated. The 
junction 3 resulted a sequence proper of the normal patient genome but not common to the 
unrelated genome, therefore it was not considered tumor specific and confirmed. Sanger 
sequencing of PCR products and their predicted size confirmed the specificity of the 
amplified segments.  
The sole confirmed variation is a translocation between chromosome 11 and X 
interesting the coding region of exon 2 of C11orf73 and the intronic region of ODZ1 between 
exon 19 and 18 (Figure 3.10).  
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Figure 3.7: Gel electrophoresis of PCR products generated using primer designed on the two 
sides of the junction sequences. Primers for junction 1,2 and 3 were used for amplify the 
candidate junction sequences in tumor and normal DNA from the studies patient and from an 
unrelated male human genome. A positive control provided with PCR amplification kit was 
included. Marker size confirmed the expected size of PCR products.   
 
Copy number aberrations 
Copy number aberrations were evaluated using array CGH and estimated from whole 
genome sequencing data using CGA tool. These results were remarkably similar, except for 
small discordant regions possibly related to CN variation that has been subtracted by NGS 
sequencing but not from array CGH data (Figure 3.8). Figure 3.10 summarizes the results of 
whole genome sequencing.   
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Figure 3.8: CGH estimated by CGA tool from whole genome sequencing data (NGS) and 
from array CGH are compared. Region of CN gain (blue) and CN loss (red) are reported for 
the autosomal chromosomes 1-22. Each chromosome is reported with the short arm on the 
left.  
 
Expression of mutated genes in patient’s tumor 
The 47 mutations predicted by whole genome sequencing affect 42 genes that has 
been evaluated by RNA sequencing. Transcriptome sequencing results were sufficient to 
evaluate highly and moderate expressed genes. Less expressed genes did not have an enough 
number of copies of mRNA to be captured from this analysis. The expression of a gene is 
directly related to the number of reads (short sequences generated by high throughput 
sequencing) able to map to its genomic position. Reads, generated by transcriptome 
sequencing, were aligned to the reference genome (hg19) using GSNAP and gene expression 
estimated by FPKM value calculated using Cufflink194. Figure 3.9 summarizes the results of 
gene expression analysis. The predicted mutations were observed only in PHF15, WDR70, 
PCNXL3, BCOR and SFXN2. For the other gene, the predicted mutation was not identified 
in the expressed RNA. For the remaining mutations confirmed by Sanger sequencing, 
VN1R5 and PPP1R3A were not captured by this analysis because not enough expressed. 
Whereas, SRGAP1 and PION, even if expressed, did not have reads coverage in the mutation 
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locus, thus they can not be confirmed or excluded using RNA sequencing data.  Expression 
data estimated for this patient were in line to those identified using the same technology from 
a group of 11 TETs (7 thymomas and 4 thymic carcinomas) and 3 TET cell lines.  26 of the 
candidate mutate genes were annotated in COSMIC database as they have been previously 
described mutated in cancer patients.  
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Figure 3.9: Expression of candidate mutated genes using transcriptome-sequencing data. (A) 
For each candidate mutated gene, FPKM value was calculated using cufflink; error bars 
report the 95%CI related to the prediction of gene expression. Genes labeled by * are those 
reported mutated in COSMIC database. (B) Average expression of candidate mutated genes 
in a series of thymic epithelial tumors: 11 patients neoplasm and 3 cell lines. Error bars 
represent the standard deviation of gene FPKM values obtained in the 14 transcriptomes.  
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Figure 3.10: summary of confirmed mutations in thymoma B3 patient’s genome. (A) 
Confirmed single nucleotide variations and INDEL. (B) Genomic coordinates: chromosomes 
and their bands, crentromeres are marked in red. (C) CN aberrations: CN gain are reported in 
green and CN losses in red, whereas diploid regions in blue. (D) Junctions’ track reports the 
t(11;X).   
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Function of mutated genes and their relevance in cancer 
Limited data are available on the role in tumor growth of the genes identified mutated 
by whole genome sequencing. The normal biological activity of VN1R5, SFXN3, PCNXl3 
and SRGAP1 is only marginally elucidated. PION is involved in amyloid beta production and 
it has been reported mutated in cancer in cosmic database, however its relevance to cancer 
growth is undetermined.  
PHF15 known also as JADE2 belongs to a family of more than 100 proteins 
characterized by the Plant Homo Domain (PHD) finger. Very limited data are available for 
this gene. Several of the PHF proteins are localized in the nucleus, and are involved in 
chromatin-mediated gene regulation.  Other members of PHF family are ASH1L, MLL and 
AIRE. The function of JADE2 is largely unknown; however, more details are available on 
the junction of JADE1 (PHF17) that presents tumor suppressor activity in kidney cancer. 
JADE1 is normally stabilized by VHL protein and prevents tumor growth by inducing 
apoptosis195.  When over-expressed, JADE1 can increase histone H4 acetylation in vivo196.  
PPP1R3A encoded for the regulatory subunit of a protein phosphatase glycogen-
associated presents in skeletal muscle. Mutations for this gene have been described in cosmic 
for different type of tumors. A possible relation between PPP1R3A mutations and colon 
cancer metastases was described197 as well as a reduced expression in breast tumors198. 
BCOR is corepressor of several transcription factors, firstly discovered for its ability 
to inhibit BCL6 through the BCOR-BCL6 binding domain199. BCOR is an essential 
transcriptom repressor for hemopoiesis, mesenchymal stem cell and early embryo 
development200,201. Germline BCOR mutations cause the Oculofaciocardiodental syndrome, 
an inherited X-linked syndrome characterized by cardiac defects and dysmorphic 
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appearance202. BCOR has been recently described to be mutated in a subset of acute myeloid 
leukemia patients203; about 50% of them present both BCOR and DNMT3A mutations 
suggesting a possible cooperation of the two genes, possibly through interference with 
epigenetic mechanisms203. BCOR may increase its transcriptional repression interacting with 
epigenetic regulators such as class I and II HDACs or the polycomb group protein. 
Of the genes involved in the translocation t(11;X), C11orf73 codes for a protein 
relevant for lung development such as demonstrated in knockout mice that present severe 
emphysema at birth and disorganization of Golgi apparatus in Clara cells204. ODZ1 belongs 
to the tenascin family and teneurin subfamily. It is a transmembrane protein type II and may 
function as cellular signal transducer forming dimmers with the other members of teneurin 
family. It is predominantly expressed in the developing nervous system205. The role of 
C11orf73 and ODZ1 in cancer is unknown. 
 A more precise characterization of the function of the mutated genes is necessary to 
understand their relevance to thymoma growth. Moreover, it is useful understand the 
frequency of these mutations in TETs to eventually identify those that are recurrent and may 
be relevant to disease pathogenesis. Because any of these genes is an obvious oncogene or 
tumor suppressor gene, an high throughout approach was adopted to evaluated mutations in a 
cohort of 26 patients.    
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3.4 Exome sequencing and transcriptome sequencing 
Whole exome sequencing, transcriptome sequencing and array CGH were performed 
on frozen material from 26 patients, in order to identify which tumor specific mutations are 
recurrent in TETs and, therefore, may drive the cancer growth. Moreover, the identification 
of recurrent mutations could offer druggable targets for therapy. From a series 55 TETs, 8µm 
frozen sections were cut, colored by H&E and reviewed by a pathologist: only tumors 
presenting more than 80% of cancer cells on histological grounds were included in this study. 
Part of the frozen tumor was scraped and RNA and DNA were extracted from the same 
specimen using All prep RNA/DNA kit (Qiagen). The tumor DNA was further tested to 
estimate the presence of tumor cells by array CGH. Because CN aberrations are only in 
tumor cells, the ability to detect aberration with a mean Log2Ratio higher than 0.3 supported 
the presence of a sufficient low normal cell infiltration. An exception was type A thymomas 
that usually do not show any CN aberration; however these tumors do not present a 
significant normal thymocyte infiltration. Considered the expected depth of coverage of 
exome sequencing, a restricted infiltration of normal cell was required to have chance to 
identify tumor mutations.  
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CGH results 
Figure 3.11 depicts the frequency of CN aberrations in the 26 tumors that passes the 
previously stated filters.  
 
Figure 3.11: Frequency of CN gain was reported in blue and CN loss in red across the 22 
autosomic chromosomes.  Frequency of aberration according to WHO histotype was reported 
on the bottom of the figure. There were 4 type A and 1 type AB that have been grouped 
together because the small numbers.  
 
Concordantly with previously reported CGH data, a more quiet patter of aberrations 
was observed in type A thymomas. In B3 thymomas and thymic carcinomas a more complex 
karyotype was appreciated. To be noted that all the samples were hybridized against the same 
male normal genome DNA (Promega) therefore CN variations are famished to tumor specific 
CN aberrations. CN variations are defined as increases or decreases in CN of a genomic 
region between persons. Thus, such CN variations are a recently discovered and pervasive 
form of inter-individual genomic variability and depending on their frequency can be 
considered in the same way as polymorphisms. Variations interesting genomic regions long 
less than 1kb are named INDELS; whereas, CN variations are those longer than 1kb. 99% of 
  ‐ 113 ‐ 
CN variations interest a region shorter than 2.8kb206. CN variation affect about 10% of 
human normal genome207 and may be associated with the susceptibility to develop 
neoplasms207; however, they are not tumor specific being present in the germeline DNA. 
Even if interesting, CN variations are not the topic of our research and this evaluation has not 
the power and was not designed to draw reliable conclusions on CN variations. Databases list 
described CN variations; therefore, such data can be used to interpret CGH results.  
CN aberrations candidate to drive the cancer grow were evaluate by the systematic 
statistical algorithm called GISTIC208. This test scores the frequency and amplitude (Log2 
ratio) of CN aberrations across the sample set. To assess chromosomal regions that 
significantly associate with CN aberrations, GISTIC identifies regions with scores above the 
random aberrations simulated by null distribution. The generated p-values were corrected for 
multiple hypotheses testing by Benjamini-Hochberg FDR procedure to obtain q-values208. Q-
value < 0.25 was considered significant, as previously described209. Table 3.8 reports the 
significant peaks individuated using GISTIC.  
  ‐ 114 ‐ 
 
Table 3.8: for each peak are listed the top region of the peak (region) and the peak 
boundaries (Extended region). Peak boundaries were determined so that the change in the 
GISTIC score from peak to boundary had < 5% likelihood of occurring by random 
fluctuation. G-Score (>1) and Q-bound (<0.25) summarized the GISTIC statistics. 
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Among the peaks identified by GISTIC two presented CN aberrations with peculiar 
characteristics. The peak of CN loss interesting chromosome 9p21.3 was constituted by 5 
tumors with CN loss, two of them showed a remarkably low Log2ratio compatible with 
homozygous CN loss. Different breakpoints defined these 2 regions, thus, the probability that 
they were related to CN variation was limited. Moreover, these CN losses interested a limited 
region of the genome; therefore, it was easy to point out CDKN2A and CDKN2B, two well-
characterized tumor suppressor genes. Tumors with CDKN2A/B CN loss were 1 B2, 1 B3 
thymoma and 1 thymic carcinoma plus 2 thymic carcinomas with the lower intensity CN loss. 
Similarly, the peak of CN gain of 18q21.33 was constituted by CN aberrations from 9 
tumors; 4 of them showed a remarkably high Log2Ratio related to the high number of copies 
predicted for this region.  
The chance that these CN aberrations were related to CN variations was limited 
because they did not showed breakpoint in the same position. The 9 regions of CN gain 
differed in the breakpoint positions reducing the chance to be related to common CN 
variations. Moreover, these aberrations interested a narrow region of chromosome 18 
containing only BCL2 locus.  Patients carrying BCL2 CN gain were 1 type A, 2 B2, 1B3 and 
5 thymic carcinomas 4 of them with gene amplification at very high Log2Ratio.  
CN variations sharing the same breakpoints to these CN aberrations have not been 
described in literature, to date. Any CN variation for BCL2 locus has been described, 
whereas the presence of CN variations, interesting CDKN2A/B loci, has been reported in 
subjects with familiar melanoma syndrome.  
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Figure 3.12: depicts circled in red (A) CDKN2A/B CN loss in the short arm of chromosome 
9 and (B) BCL2 amplification in chromosome 18. To be noted the remarkable deviation from 
the baseline copy number of these aberrations (low and high Log2ratio, respectively) and the 
small extension in base pairs.  
 
Exome sequencing results 
Among these tumors we selected 5 cases: 2 TC, 2 B3 and 1 B2 thymoma to perform 
whole exome sequencing. Paired normal DNA for these patients was extracted from 
peripheral blood using QIAamp Blood Maxi kit (Qiagen). Mutations were classified in SNVs 
and INDELS. Among the INDELS those interesting <5bp are confidently called using GATK 
tool kit (Broad Institude, Cambridge MA) on reads aligned by Novoalign (Novochraft) to 
hg19, INDELS 5<x<10bp can be called sometime, whereas INDELS 10-1000kb are of 
difficult identification with the adopted technology. Only mutations affecting the coding 
exons with nonsynonymous amino acid modification were evaluated. Mutations previously 
described as SNP in dbSNP132 were excluded by the analysis with the exception of those 
mutations also described in cancer and reported in COSMIC database.  
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Table 3.9: Somatic Mutations in Thymic epithelial tumors 
Thymoma Thymic Carcinoma 
B2 B3 B3 TC TC 
P-Thy016 P-Thy001 P-Thy015 N-Thy011 P-Thy003 
ID2 K1N ABTBA748V ACAT1 I52T ADAMTS9 S1479N ASH1L M1427T 
ADAMTS9 S1479N AC099759.1A183V AMPD2 E279G C13orf31 A86T C10orf112 R195K 
 DCHS1 L460V C20orf186 R69* CYLD Q493* C6orf221 Q204* 
 GABRA1 Y196C JMJD1C D779V EXOG G146E COL15A1 G856* 
 MYOCD R402* LRBA I275T GABBR2 L252V DNAH3 Y3008S 
 PRSS12 N507D MYO5A Y263C GIMAP8 R164* EPB41L4B D371N 
 RNF103 R590K NETO1 R206Q GLI2 R103C EXOC1 Q26R 
 USP17S23P TMEM50A W37G ITGB2*410G GRM8 M27K 
 SMG6 Y623* UBR1 P181T KIAA1609 R265H HRAS Q61R 
 SPATA16 N105K ZNF479 R11* LRP2 R2336W JPH3 V253I 
 TBC1D26 C328S  NEFM R54C KLC2 W491* 
 TCTEX1D1 R54H  NLRC5 R400* LDB3 T425S 
 TRIML1 P433L  PAXIP1 P755S MEF2C F109Y 
   PBRM1 R1675W MRPL53 L17F 
   PCDH12 R498H NAT10 K1017E 
   PEX1 V429I NIPBL W2107G 
   TMEM2 T276M SHISA6 R256* 
   TMX4 C326R SLC34A2 R623H 
   ZNF521 R185K SLC4A2 A463T 
    TEAD4 A54T 
    TP53 R342* 
    TTN D24617H 
 AL445989.1 
18_SUB_CGYGSGYGY/Y 
 DNMT3B 
R420_Frameshift 
CDKN2A 
A106_Frameshift 
 
 
The exome sequencing results revealed a remarkable heterogeneity of mutations between 
tumors, without any recurrent mutation identified. Probably, the small number of cases 
evaluated, together with the tumor heterogeneity, limited the chance do identified recurrent 
events. In this small group a trend through a more complex pattern of mutation was observed 
from B2 to thymic carcinomas. Interestingly, one thymic carcinoma presented TP53, HRAS 
SNVs and CDKN2A insertion of a cytosine into the codon 107 with consequent frame shift 
mutation of the protein. KIT mutations were not detected. 
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Transcriptome sequencing results 
Expression analysis of mutated genes enables data confirmation together with a 
functional interpretation of the observed changes. Transcriptome sequencing is a powerful 
method to evaluate expression of genes and the presence of known mutations on genomic 
scale. Table 3.10 summarized these expression results for the mutations identified from 
exome sequencing. 
Table 3.10: Confirmed mutations by transcriptome sequencing 
Thymoma Thymic Carcinoma 
B2 B3 B3 TC TC 
P-Thy016 P-Thy001 P-Thy015 N-Thy011 P-Thy003 
ID2 K1N ABTBA748V ACAT1 I52T ADAMTS9 S1479N ASH1L M1427T 
 GABRA1Y196C AMPD2 E279G C13orf31 A86T HRAS Q61R 
 PRSS12 N507D JMJD1C D779V CYLD Q493* MRPL53 L17F 
 RNF103 R590K LRBA I275T ITGB2*410G NAT10 K1017E 
 TCTEX1D1R54H MYO5A Y263C KIAA1609 R265H NIPBL W2107G 
   PAXIP1 P755S SLC34A2 R623H 
   PBRM1 R1675W SLC4A2 A463T 
   PEX1 V429I TEAD4 A54T 
   TMEM2 T276M TP53 R342* 
   TMX4 C326R CDKN2A A106_FS 
     
     
 
The expression of the mutated genes suggests their possible role in cancer growth. 
However, it remains do be determined if the identified mutations can affect the function of 
the translated protein. The INDEL affecting CDKN2A modify its structure introducing a 
frame shift mutation. This mutation and interests the ankyrin repeat domain (30-130AA) of 
p16INK4 necessary for CDK4 inhibition210. For alterative splicing, p14ARF can be translated 
from CDKN2A gene; in this sequence the INDEL occupies 118AA and affects the carboxyl-
terminal domain necessary for nucleolar localization but not for MDM2 binging211. For 
SNVs, Sorting Tolerant From Intolerant (SIFT) algorithm was adopted to predict the effect of 
the mutation on protein structure212. Briefly, SIFT assumes that important positions in a 
protein sequence are conserved throughout related species and, consequently, substitutions at 
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these positions can affect protein function212. SIFT scores and predicted effects are reported 
in table 3.11. 
Table 3.11: Prediction of mutation of protein function 
Patient Gene Protein ensembl ID Substitution Prediction SIFT Score 
P-Thy016 ID2  ENSP00000379585 K1N N/A N/A 
P-Thy001 ABTB2 ENSP00000298992 A748V TOLERATED 0.14 
P-Thy001 GABRA1 ENSP00000023897 Y196C DAMAGING 0 
P-Thy001 PRSS12 ENSP00000296498 N507D TOLERATED 0.18 
P-Thy001 RNF103 ENSP00000237455 R590K TOLERATED 0.93 
P-Thy001 TCTEX1D1 ENSP00000282670 R54H TOLERATED 0.3 
P-Thy015 ACAT1 ENSP00000265838 I52T TOLERATED 0.16 
P-Thy015 AMPD2 ENSP00000256578 E279G TOLERATED 0.18 
P-Thy015 JMJD1C ENSP00000382195 D779V DAMAGING 0 
P-Thy015 LRBA ENSP00000349629 I275T TOLERATED 0.2 
P-Thy015 MYO5A ENSP00000348693 Y263C DAMAGING 0 
P-Thy015 UBR1 ENSP00000290650 P181T TOLERATED 0.55 
N-Thy011 ADAMTS9 ENSP00000295903 S1479N TOLERATED 0.32 
N-Thy011 C13orf31 ENSP00000317619 A86T DAMAGING 0 
N-Thy011 CYLD ENSP00000308928 Q493* N/A N/A 
N-Thy011 ITGB2 ENSP00000303242 *410G N/A N/A 
N-Thy011 KIAA1609 ENSP00000343635 R265H TOLERATED 0.1 
N-Thy011 PAXIP1 ENSP00000319149 P755S TOLERATED 0.3 
N-Thy011 PBRM1 ENSP00000296302 R1675W DAMAGING 0 
N-Thy011 PEX1 ENSP00000248633 V429I TOLERATED 0.42 
N-Thy011 TMEM2 ENSP00000366243 T276M TOLERATED 0.06 
N-Thy011 TMX4 ENSP00000246024 C326R TOLERATED 0.48 
P-Thy003 ASH1L ENSP00000357330 M1427T TOLERATED 0.19 
P-Thy003 HRAS ENSP00000309845 Q61R DAMAGING  0.02 
P-Thy003 MRPL53 ENSP00000258105 L17F N/A N/A 
P-Thy003 NAT10 ENSP00000257829 K1017E TOLERATED 0.14 
P-Thy003 NIPBL ENSP00000282516 W2107G TOLERATED 0.33 
P-Thy003 SLC34A2 ENSP00000371483 R623H TOLERATED 0.11 
P-Thy003 SLC4A2 ENSP00000311402 A463T TOLERATED 0.2 
P-Thy003 TEAD4 ENSP00000351184 A54T DAMAGING  0 
P-Thy003 TP53 ENSP00000269305 R342* N/A N/A 
P-Thy003 CDKN2A  ENSP00000307101 A106_FS Frameshift N/A 
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SIFT results need to be carefully interpreted because the specificity and sensitivity of 
the method: 69% and 81%, respectively; and mainly because it represents only a prediction of 
function.  
Transcriptome sequencing data were available only for one patient with possible 
homozygous CN loss of CDKN2A that expressed low level of mRNA (FPKM 0.804; 95%CI 
0-0.804) compared to the mean of the other 10 tumors evaluated by RNA sequencing average 
FPKM 38.63 (95%CI 7.838-69.42). Transcriptome sequencing data for BCL2 expression 
were available for 3 patients with BCL2 amplification and for 8 without. Three tumors with 
BCL2 amplification present an increased expression of BCL2 mRNA (p=0.0121; Figure 
3.13) and for 2 of them we had enough material to prove an increase of BCL2 protein 
expression. 
 
Figure 3.13: overexpression of BCL2 in tumor with BCL2 amplification. (A) BCL2 
expression estimated from transcriptome sequencing data was significantly higher in tumors 
with BCL2 amplification than those without. (B) BCL2 protein was expressed at increased 
level in the two thymic carcinomas with BCL2 amplification TC(3) and TC(4) than in the 
sample without: 1 thymic carcinoma  TC(1) 1 AB and 1 B2 thymoma or in 2 samples of 
normal thymus (nThy). 
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An overall remarkable heterogeneity of SNV and INDEL was observed in the studied 
samples, whereas common patterns of CN aberrations were observed. Interestingly, 
CDKN2A was mutated in different ways, INDEL in 1 case and focal very low intensity 
Log2ratio CN loss in 2 cases. Because BCL2 and CDKN2A are more likely to be mutated by 
CN aberrations we evaluated by array CGH a series of 59 FFPE TETs.   
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3.5 CGH evaluation of a series of formalin fixed paraffin embedded thymic epithelial 
tumors. 
FFPE material is a valuable repository of tumor DNA stored for several years. 
Because the rarity of these tumors, the chance to evaluate archive material is necessary to 
correlate molecular aberrations with patients outcome. Several years are necessary to reach a 
mature follow up for these tumors. The newly available Agilent ULS labeling kit enables us 
to perform array CGH using FFPE tumor tissue.  
A series of 132 patients affected by TETs were consecutively operated at the Istituto 
Clinico Humanitas (Rozzano, Milan, Italy) between 1996 and 2008. Clinical data were 
retrospectively collected. The main patient and tumor characteristics are summarized in Table 
3.12. The median age was 55 years and the male:female ratio was of 1:1. Most of the patients 
had an early stage of the disease (68% stage I and II) and underwent a radical resection (R0, 
71%). Survival was assessable in all patients, and median follow up was 7 years (84.5 
months; 95%CI 72.1-96.9). Thirty-one patients (23.5%) were reported to be dead at the 
update performed in June 2009. The median overall survival (OS) was 31.5 years (377.8 
months; 95%CI 112.5-634.2) with a 10-year OS of 70% (Figure 3.14A). Only 13 patients 
(9.8%) died because of disease progression, 2 patients died because of myasthenia gravis and 
4 because of a secondary cancer (3 hepatocellular carcinomas and 1 non-small cell carcinoma 
of the lung). The median Disease-Related Survival (DRS) was not reached after 32 years 
follow-up. The 10-year DRS was 87% (Figure 3.14B). Considering the median age of 55 and 
the indolent clinical behavior of most tumors, DRS was chose over OS for further survival 
analyses.  
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A total of 131 patients were evaluable for TTP; for 1 patient no updated data on the 
progression date were available. Thirty-six patients developed progression during the period 
of study. The median TTP was 12.3 years (147 months; 95%CI 121.6-172.4), and the 10-year 
TTP rate was 69% (Figure 3.14C).  
In the univariate analysis for DRS, stage (I-II vs III-IV; Logrank p=0.017, Figure 
3.14D) and WHO classification (A-Ab-B1 vs the other; p=0.087) but not completeness of 
resection (R0 vs R1-R2; p=0.388) were significant.  In the multivariate analysis any 
independent prognostic factor was observed. The univariate analysis for TTP revealed stage 
(p=0.0027), completeness of resection (p0.025) and WHO classification (p=0.0001) to be 
prognostic factors in TETs. However, the Cox hazard model demonstrated that only WHO 
classification was an independent prognostic factor in this series (p=0.0099). Data regarding 
paraneoplastic syndromes were available in 125 patients: 32 (25.6%) developed myasthenia 
gravis during the course of the disease, one patient developed autoimmune encephalopathy 
and one patient autoimmune glomerulonephritis. Paraneoplastic syndromes did not have a 
significant impact on survival. An haematoxylin and eosin stained slide from each tumor 
sample was revised by a pathologist and regions with >80% of tumor cells were selected for 
macro-dissection. DNA was extracted and used for CGH analysis. 
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Table 3.12: patients’ characteristics. Na*, patients for whom data are not available at 
diagnosis. Other#, 1 micronodular and 1 cystic thymoma. MG: Myasthenia Gravis. Other+, 1 
autoimmune glomerulonephritis (in the array CGH analysis) and 1 autoimmune 
encephalopathy. TTP, Time to progression. DRS, disease-related survival. 
 
Table 3.12: Patient characteristics 
  Total (132) aCGH (59) 
Median Age (range), years  55 (20-86) 57 (20-86) 
Sex Male:Female 67 : 65 28 : 31 
Tumor sample Primary tumor 108 (82%) 46(78%) 
 Relapsed 24 (18%) 13(22%) 
Stage I 35/114 (31%) 15/49 (31%) 
 II A 26/114 (23%) 9/49 (18%) 
 II B 17/114 (15%) 5/49 (10%) 
 III A 16/114(14%) 7/49 (14%) 
 III B 3/114 (3%) 2/49 (4%) 
 IV A 5/114 (4%) 3/49 (6%) 
 IV B 12/114 (11%) 8/49 (16%) 
 Na* 18 10 
Completeness of resection R0 79/112 (71%) 33/47 (70%) 
 R1 23/112(21%) 7/47 (14%) 
 R2 10/112(9%) 7/47 (14%) 
 Na* 20 12 
WHO histotype A 15/132 (11%) 12/59 (20%) 
 AB 28/132  (21%) 14/59(24%) 
 B1 24/132  (18%) 0 
 B1/B2 6/132  (5%) 0 
 B2 8/132  (6%) 1/59 (2%) 
 B2,B3 11/132  (8%) 5/59 (8%) 
 B3 24/132  (18%) 20/59 (34%) 
 C 14/132  (11%) 7/59 (12%) 
 Other# 2/132 (2%) 0 
Paraneoplastic Syndromes MG 32/125 (26%) 17/58 (29%) 
 Other+ 2/125 (2%) 1/58 (2%) 
10-year DRS  87% 83% 
10-year TTP  69% 65% 
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Figure 3.14: Kaplan-Meier survival estimate curves for A) Overall Survival, B) Disease-
Related Survival, C) Progression-Free Survival, D) Disease-Related Survival for patients 
with stages I and II versus stages III and IV. 
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Correlation between chromosome arm-level aberrations and thymic epithelial tumor 
histotypes 
 The distribution of CN aberrations was calculated according to their length, which 
was expressed as percentage of the CN aberrations in relation to the respective chromosome 
arm. Small CN aberrations (0-10% of a chromosome arm length) were the most common 
(Figure 3.15A; n=3665). The number of CN aberrations progressively decreased in inverse 
proportion to their length up to 80% of their respective chromosome arms, and then rose 
again reaching a second peak at 90-100%. Based on the equation of the CN aberration 
distribution observed for up to 80% of chromosome arm-length, the number of 90-100% arm 
length CN aberrations was much higher than expected (90 instead of 7; χ2 p<0.001). This 
observation suggests that small (focal) and long arm-level aberrations might represent distinct 
types of CN aberrations and therefore they need to be analyzed separately. 
Figure 3.15B depicts the frequency of arm-level CN aberrations and their distribution 
according to TET histotypes. Only CN aberrations cumulatively covering more than 80% of 
an arm were defined as arm-level CN aberrations. Hierarchical cluster analysis of histotype 
profile indicated a close relatedness between B3 and TC. B2+B2/B3, AB and A types were 
incrementally dissimilar to TCs (Figure 3.15B). Type A thymoma showed occasional 
chromosome arm-level CN aberrations. On the contrary, types B3 and TC shared frequent 
arm level CN gains of 1q, as well as losses of chromosomes 6 and 13q. In addition, TC 
presented frequent losses of 16p and 17q. Although the potential continuum with A subtypes 
is impossible to evaluate due to excess of non-neoplastic thymocytes in the intermediate 
histotypes, our results support the presence of a continuum of genomic aberrations between 
B2/B3, B3 and TC histotypes (Figure 3.15B).  
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Chromosome arm-level CN loss of 13q is a candidate marker of poor prognosis  
Loss of 13q was associated with a poorer TTP (log rank p=0.013; Figure 3.15C) and 
DRS (p=0.063; Figure 3.15D). Arm-level CN loss of 13q was found only in more aggressive 
histotypes (B3 and TC). Deletions of the whole or parts of chromosome 13 have been shown 
to have survival implications in other tumors, such as multiple myeloma (whole chromosome 
13) 213 and breast cancer (13q12-13) 214. The limited number of tumors carrying chr13 arm 
level CN loss limits the possibility to draw definitive conclusion on this candidate prognostic 
marker. Thus, confirmation in an independent series is recommended.  
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Figure 3.15: Arm-level CN aberrations in thymic epithelial tumors identified by array CGH. 
(A) Arm-level CN aberrations were divided into 10 categories according to their cumulative 
lengths covering the percentage of their respective mapping chromosome arm. The number of 
CN aberrations cumulatively covering <10% of the chromosome arm-length were the most 
abundant.  The power function y=6.5636x-2.546 summarizes the distribution of CN aberrations 
based on chromosome arm-length from 0 to 80%, and based on this equation the expected 
number of 90-100% arm length CN aberrations was 7 instead of 90 observed (χ2 p<0.001). 
(B) Arm level CN gains (red) and losses (blue) of autosomal chromosomes. The top panel 
depicts the overall summary of frequency of arm level CN aberrations. The arm level CN 
aberrations grouped by histotype (A, AB, B2+B2/B3, B3 and TC) are summarized in the 
bottom panel. * indicates B2 and B2/B3. Thymic carcinomas and B3 thymomas exhibit 
similar patterns of arm level CN aberrations. Only few arm level CN aberrations were 
observed in A thymomas. (C) Time to progression curves in relation to 13q CN loss. (D) 
Disease related survival curves in relation to 13q CN loss.  
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Identification of significant CN aberrations in thymic epithelial tumors by GISTIC 
algorithm 
In order to identify CN aberrations driving the cancer phenotype, we applied the 
GISTIC algorithm 208 to TET array CGH data. Q-value < 0.25 was considered significant. 
We identified 72 peaks of CN gain (817 genes + 23 miRNAs) and 54 of CN loss (155 genes 
+ 3 miRNAs) (Figure 3.16A and B). 
Of the genes mapped into GISTIC peaks, known cancer-related genes were selected 
and depicted in Figure 3.16A and 3.16B based on the following criteria: (1) those present in 
focal GISTIC peaks (< 5Mb), (2) recurrent (occurred in at least 2 tumors) and (3) and in 
peaks containing few genes (<15 genes). CN aberrations of CDK4, CDKN2A/B and IKBKB 
have been previously reported in other tumors 209. Other known cancer-related genes 
identified in our analysis include HRAS and AKT/mTOR pathway signal transduction genes 
(PIK3CD and ATK1), or belong to FGF receptor family (FGFR3).  Interestingly many genes 
regulating programmed cell death were also found in GISTIC peaks  (BCL2, BCL-XL, 
PDCD1, CRK) suggesting an important role of apoptosis in TET pathogenesis. Moreover, 
CN loss of a DNA damage repair gene FANCF suggests a link with BRCA/ATM pathway 
and uncontrolled cell cycle progression 215.  
To further narrow down candidate genes potentially relevant to TET biology, we 
evaluated the implication of CN aberrations on survival. The CN status of each gene locus 
was assessed in relation to DRS. A total of 418 genes (373 in CN gain; 45 in CN loss) and 15 
miRNAs (11 in CN gain and 4 in CN loss) were found to be associated with DRS (p<0.05). 
Thirty-eight genes and two miRNAs were located in 6 GISTIC significant peaks (Figure 
3.16C). We then assessed which of the 40 loci were also significantly associated with TTP (p 
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< 0.05). Only two loci significantly correlated with both poor DRS and TTP: CN gain of 
BCL2 and homozygous loss of CDKN2A/B loci (Figure 3.16C). The results of this 
exploratory analysis allowed us to pinpoint candidate genes relevant for tumor biology, to be 
further experimentally validated. The presence of other important genes for cancer growth 
was not excludible because the relative small number of tumor limited the statistical power of 
this analysis. However, this is larger series of array CGH in TETs to date. 
 
CDKN2A CN loss correlates with low p16INK4 expression and poor prognosis  
 Cases carrying homozygous 9p21.3 CN loss (2 B3 thymomas and 2 TCs) had a 
significantly worse DRS (Log Rank p=0.021) and TTP (Log Rank p=0.019). Focal deletion 
of 9p21.3 is a frequent event in cancer (40% overall and 16% focal CN loss) 209, and poor 
outcome for patients carrying 9p21.3 deletion has also been described in lymphoblastic 
leukemia 216. This region contains two known tumor suppressor genes, CDKN2A and 
CDKN2B. We confirmed array CGH CN loss of CDKN2A locus by CN-PCR. Copy number 
losses of CDKN2A locus were evaluated in 5 samples without and 4 samples with CDKN2A 
CN loss identified by CGH, and CGH results were confirmed in all samples (Fisher exact test 
p= 0.008). 
We evaluated p16INK4 expression in TET samples using a tissue microarray 
containing 132 TET tumors, which include those evaluated by array CGH. None of the 5 
tumors carrying 9p21.3 CN loss expressed p16NK4. Out of 119 evaluable cases, 34 were 
positive for p16INK4, which correlated with better DRS (Figure 3.16D and E; log rank 
p=0.041). These data suggest p16INK4 as a potential prognostic factor in TET. Interestingly, 
61% of the primary TETs (34/56) and the three TET cell lines showed no detectable 
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p16INK4 expression in the absence of CDKN2A CN loss (Figure 3.16F) indicating that 
negative p16INK4 expression was not exclusively due to CDKN2A CN loss. The loss of 
p16INK4 expression in those tumors could be related to p16INK4 promoter methylation 
147,153 or miR-24 deregulation 217.  
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Figure 3.16: Identification of significant CN aberration peaks with survival implications. (A) 
Peaks of CN gain and (B) CN loss identified by GISTIC algorithm. GISTIC q-values (x-axis) 
are plotted across the genome (y-axis). q value of 0.25 was used as cut-off value for 
significance (blue line). 13 cancer-related genes were identified in the GISTIC peaks. (C) 
Venn Diagram summarizes significant CN aberration peaks identified by GISTIC (left circle) 
and genes that were related to significant differences in disease-related survival (right circle). 
There were 40 shared-genes between the two groups. Only two genes were also significantly 
related to time to progression. TTP, time to progression; DRS, disease-related survival. (D) 
Disease-related survival in relation to CDKN2A expression evaluated by 
immunohistochemistry. (E) Representative p16INK4 positive and negative cases out of 119 
thymic epithelial tumor samples evaluated by immunohistochemistry staining on tissue 
microarray. (F) p16INK4 expression in thymic epithelia tumor cell lines by Western blot. α-
tubulin was used as loading control.  
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Table 3.13: Immunohistochemistry results for CDKN2A 
  p16INK4 
 Total G0 G1 G2 G3 
Total 132 85 25 8 1 
      
Female 65 43 15 3 1 
Male  67 42 10 5 0 
Tumor samples      
Primary  108 69 19 7 1 
Relapse 24 16 6 1 0 
Stage      
I 35 26 7 0 0 
IIA 26 15 6 5 0 
IIB 17 10 2 2 0 
IIIA 16 7 4 1 0 
IIIB 3 2 1 0 0 
IVA 5 3 0 0 1 
IVB 12 8 1 0 0 
Na* 18     
Completeness of resection      
R0 79 50 14 5 1 
R1 23 15 5 2 0 
R2 10 6 1 0 0 
Na 20     
WHO histotype      
A 15 6 5 1 0 
AB 28 17 6 3 0 
B1 24 18 5 0 0 
B1/B2 6 4 0 1 0 
B2 8 6 1 0 0 
B2/B3 11 6 2 1 1 
B3 24 16 5 1 0 
C 14 10 1 1 0 
Others 2     
Paraneoplastic syndromes      
No 91 60 15 7 1 
Yes 34 21 10 0 0 
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Deregulation of BCL2 family genes in thymic epithelial tumors 
BCL2 locus presented CN gain in 10% (6 out of 59) of the TET samples, including 1 
type A, 2 B3 thymomas and 3 TCs.  
Consistently with previous reports, MCL1 and BCL2 were frequently co-expressed in 
thymic carcinomas 131 and MCL1 CN gain is a frequent event in several cancers 209 We 
observed MCL1 CN gain in 51% of all TET cases especially in B3 (70%) and TC (57%). 
However, this CN gain was mainly the result of the whole 1q gain rather than focal MCL1 
CN amplification.  
To evaluate the significance of BCL2 and MCL1 CN aberrations in TETs, we studied 
the expression of BCL2 family genes in three TET cell lines.  BCL2 expression was higher in 
TY82 and T1682 than in T1889 (Figure 3.17A), in agreement with the array CGH results 
showing that T1889 but not T1682 or TY82 carries CN loss of the BCL2 locus. In TET cell 
lines, BCL2 is co-expressed with other anti-apoptotic BCL2 family members (Figure 3.17A). 
While all TET cell lines expressed BAK, BAX expression was prominent only in T1682 
(Figure 3.17A).  To further dissect the significance of BCL2 family genes in TETs, BCL2, 
MCL1, BCL-XL, BCL-W and A1 were depleted in T1889, TY82 and T1689 cells by siRNA 
approaches, one by one (Figure 3.17B). Four siRNA plus the pull of them were used to knock 
down protein expression; a scramble siRNA was used as control. The extent of knock down 
and MTS assay results were correlated using a linear regression model. BCL2 knockdown 
significantly correlated significantly with the reduction of proliferation in all 3 cell-lines 
whereas MCL1 played a role only in T1889 and TY82 cells (Figure 3,17B). The results 
suggest that these cells may be addicted to BCL2 and MCL1 for growth (Figure 3.17D). 
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Taken together, these data suggest that BCL2 family genes are deregulated in TET cells and 
may play important roles in maintaining TET cell growth/survival. 
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Figure 3.17: Deregulation of Bcl-2 family member genes in thymic epithelial tumors. (A) 
Expression of BCL2 anti-apoptotic and pro-apoptotic family members in thymic epithelial 
tumor cell lines. (B) Correlation between protein expression after siRNA knockdown of anti-
apoptotic BCL2 family proteins (X axis) and inhibition of thymic epithelial tumor cell 
proliferation (Y axis). After 48 hours protein expression was evaluated by western blot in 
untreated cells and after transfection of siRNA pool, 4 individual siRNAs or scrambled 
siRNA (scRNA) as control. After 72 hours proliferation was tested by MTS assay in mock-
transfected and transfected cells. MTS results were normalized to those of untreated cells, 
whereas protein expression to Tubulin-α and reported as percentage of protein expression in 
scRNA transfected cells.  scRNA refers to scramble siRNA transfected cells; R2 indicates the 
determination coefficient and * denotes those p values <0.05 considered significant. (C) 
Results on proliferation of thymic epithelial tumor cell lines of the 2 most effective siRNA in 
knockdown of anti-apoptotic BCL2 family proteins. Data are normalized to untreated cells.  
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Thymic epithelial tumor cell lines are resistant to ABT263 treatment but sensitive to the 
combination with sorafenib 
The dependence of TET cell growth on BCL2 and MCL1 (Figure 3.18B and C) 
prompted us to evaluate the potential application of these targets for treatment. For this 
purpose, we analyzed the sensitivity of the three TET cell lines to ABT263, a small-molecule 
BH3 mimetic that inhibits the anti-apoptotic proteins Bcl-2, Bcl-xL and Bcl-w 218. All TET 
cell lines were relatively resistant to ABT263 (Figure 3.18A), similar to an ABT263-resistant 
small cell lung cancer cell line (H82) that does not express BCL2 218. Resistance to ABT263 
treatment has been linked to MCL1 expression 218. Although T1682 expressed low level of 
MCL1, T1682 cells (IC50  = 2.52 uM) were highly resistant to ABT263 in MTS assay as 
compared to ABT263-sensitive H146 small cell lung cancer cells (IC50 = 33 nM) (Figure 
3.10A), which may be attributed to the observation that ABT263 induced MCL1 expression 
in T1682 cells (Figure 3.18C). Sorafenib significantly attenuated MCL1 expression in MCL1 
expressing TY82 and T1889 cell lines (Figure 3.18D). Sorafenib has recently been shown to 
be able to reduce MCL1 expression in cancer cells 219.  Intriguingly, the combination of 
sorafenib with ABT263 was highly synergistic in preventing cell proliferation in TET cell 
lines for most of the concentrations tested (Figure 3.18E). Our study suggests that TETs with 
BCL2 family gene deregulation may be highly sensitive to sorafenib/ABT263 combination 
therapy. 
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Figure 3.18: Effect of two Bcl-2 inhibitors, ABT263 and Sorafenib, in thymic epithelial 
tumor cell lines. MTS assay of (A) ABT263 and (B) Sorafenib in thymic epithelial tumor cell 
lines and control cell lines. H146, H82 small cell lung cancer cell lines were used as 
references in ABT263 experiments 218. (C) In T1682 cells, ABT263 treatment increases 
MCL1 level compared to untreated cells or Gx15-070 treatment. (D) Treatment with 4µM 
sorafenib for 48h reduced expression of MCL1 in those thymic epithelial tumor cell lines 
with higher basal levels of MCL1 (T1889 and TY82). (E) Combination index computed by 
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Calcusyn for ABT263-sorafenib combination in three thymic epithelial tumor cell lines. 
Values <1 were considered synergistic. Detailed results are reported in table 3.14. 
 
Table 3.14: Combination Index for ABT263 plus Sorafenib treatment. 
T1889 T1682 TY82 
ABT263 
(µM) 
Sorafenib 
(µM) CIx 
ABT263 
(µM) 
Sorafenib 
(µM) CIx 
ABT263 
(µM) 
Sorafenib 
(µM) CIx 
1 1 5.893 0.1 0.1 0.293 0.1 0.1 0.439 
3.49 5.58 0.03 0.5 0.5 0.465 1 1 0.792 
3.97 6.98 0.04 1 1 0.665 1.3 2.77 0.83 
5 5 0.087 2.22 1.21 0.07 1.48 3.46 0.18 
5.96 10.47 0.04 2.52 1.51 0.05 5 5 0.034 
7.94 13.96 0.02 5 5 1.05 2.22 5.19 0.02 
10 10 0.153 3.78 2.27 0.04 2.96 6.92 <0.01 
   5.04 3.02 0.01 10 10 0.07 
   10 10 0.736    
List the results of the combination treatment for ABT263 and sorafenib, calculated using 
Calcusyn. Several doses of the two drugs were used for thymic epithelial tumor cell lines. 
CIx= combination index; Most values constitute synergistic combinations (CI < 1) 
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Gx15-070 inhibits thymic epithelial tumor cell growth through autophagy and necroptosis 
To further explore the role of the deregulated BCL2 family proteins in TET cells, we 
assessed the sensitivities of TET cell lines to Obatoclax (Gx15-070, a small molecule pan-
BCL2 family inhibitor) 220. All TET cell lines were remarkably sensitive to Gx15-070 with 
IC50s ranging from 36 to 100 nM (Figure 3.19A). Gx15-070 significantly suppressed the 
growth of TY82 xenografts in nude mice (Figure 3.19B). To understand the mechanism of 
action of Gx15-070 in TET cells, we studied whether Gx15-070-induced cell death is 
caspase-3 dependent after 48-h treatment (Figure 3.20A). Although upon exposure to 1000 
nM Gx15-070, 60% of T1682 cells underwent cell death, whereas at 100 nM ABT263 only 
25% of the cells were dead (Figure3.19D), western blot analysis revealed that cleavage of 
PARP and caspase-3 was predominantly observed in T1682 cells treated with ABT263 but 
not with Gx15-070 (Figure 3.19C). 
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Figure 3.19: Effect of GX15-070, (A) in thymic epithelial tumor cell lines MTS assay of 
ABT263 and Gx15-070 in thymic epithelial tumor cell lines; H157 non-small cell lung cancer 
cell line was used as negative control because reported resistant218. (B) Gx15-070 suppressed 
the growth of TY82 xenografts. Average fold change of tumor volume of 10 mice treated by 
Gx15-070 and 10 by vehicle alone were reported. The black arrow delimitates the timing of 
treatment. (C) Cleavage of PARP and caspase-3 was assessed by western blot after 48-hour 
treatment with various concentrations of GX15-070 and ABT263 in T1682 cells. (D) Cell 
death induced by Gx15-070 and ABT263 was expressed as percentage of dead cells over 
total number of cells (cell death %). Cells were treated with the indicated concentrations of 
Gx15-070 and ABT263 for 48 hours, stained with TOPRO3 followed by flow cytometry 
analysis. 
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Moreover, Gx15-070 treatment did not enhance caspase-3 activity in TET cell lines 
(Figure 3.20). In contrast, induction of caspase-3 activity was clearly observed in ABT263-
treated BCL2-positive TET cells (Figure 3.20). Together these findings suggest that Gx15-
070-induced cell death is caspase-3 independent. This notion was further supported by the 
finding that the pan-caspase inhibitor ZVAD-FMK was not able to restore cell proliferation 
after Gx15-070 treatment in TET cell lines (Figure 3.22A). 
 
Figure 3.20: Caspase 3 activity in thymic epithelial tumor cell lines treated with Gx15-070 or 
ABT263. Caspase 3 activity was determined by colorimetric activity assay kit according to 
the manufacturer’s instructions. H146 was used as a control. Activities were expressed as 
percentage of untreated cells.  
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As Gx15-070 only elicited minimal cell death in T1889 cells (Figure 3.19D), we 
examined the effect of Gx15-070 on cell proliferation. Though no sign of cell cycle arrest 
was found (data not shown), a dramatic increase of cell doubling time was observed in all 
Gx15-070-treated TET cell lines (Figure 3.21A-C). Together, our data suggest that Gx15-070 
treatment of TET cells leads to both growth inhibition and cell death.  
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Figure 3.21: Gx15-070 induces arrest of cell proliferation in thymic epithelial tumor cell 
lines. (A) The number of viable cells and dead cells was reported for thymic epithelial tumor 
cell lines and H146 after 48-hour treatment with the indicated doses of Gx15-070. Number of 
viable and dead cells was calculated using TOPRO3 to evaluate membrane permeability by 
flow cytometry. (B) Gx15-070 increases doubling times of thymic epithelial tumor cells. 
Doubling time was determined by counting the cells every 24 hours for a period of 120 hours 
in the presence (+) or absence (-) of 250nM Gx15-070. (C) Even after 48-hour drug washout 
the mean doubling time of thymic epithelial tumor cell lines was still increased for treated 
cells. Cells were exposed to Gx15-070 for 48 hours. Data were reported as mean ± standard 
deviation.  
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Because recent studies suggested that Gx15-070 induces autophagy-dependent 
necroptosis in acute lymphoblastic leukemia cells 221, we performed electron microscopy in 
TET cells: changes in mitochondrial structure were demonstrated as early signs of autophagy 
after 1h Gx15-070 treatment (Figure 3.22B). After 6-hour treatment, cytoplasm vacuolization 
and mitochondrial swelling with early signs of necroptotic cell death were evident.  
Intriguingly, cytoplasmic vacuolization, late-stage necroptotic or autophagic cell death were 
the main features 48h after Gx15-070 (1µM) treatment. Electron microscopy showed no sign 
of apoptotic cell death; consistent with the observation that caspase-3 was not involved in 
Gx15-070-induced cell death. We also examined accumulation of the autophagy marker 
LC3B-II, after Gx15-070 treatment. As shown in Figure 3.22C, LC3B-II accumulation was 
detected in all Gx15-07-treated TET cell lines and occurred as early as 1h after Gx15-070 
treatment, suggesting that Gx15-070 activates the autophagy pathway in TET cells. To 
further determine if the Gx15-070-induced cell death is necroptotic cell death and the death is 
autophagy-dependent, we evaluated the effect of necrostatin 1 (Nec1; necroptosis inhibitor) 
and chloroquine (CQ; autophagosome maturation inhibitor) in Gx15-070-treated TET cells 
and demonstrated that Gx15-070-induced growth inhibition (Figure 3.22A) and cell death 
(Figure 3.23) could be effectively rescued by necroptosis and autophagy inhibition. More 
importantly, depletion of Beclin 1 (BECN1), a key regulator of autophagy pathway, and 
RIPK1, a key regulator of necroptotic pathway (Figure 3.22D) recapitulated the results 
obtained with Nec1 and CQ (Figure 3.22A). In line with previous reports, our results suggest 
that Gx15-070-induced necroptosis and autophagy 221. 
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Figure 3.22: GX15-070 induces autophagy and necroptosis in thymic epithelial tumor cells. 
(A) Heatmap summarizes the rescue effects of caspase (50 µM ZVAD-FMK), necroptosis 
(30 µM NEC1), and autophagosome maturation (25 µM CQ) inhibitors on GX15-070-
induced growth inhibition. Percentage of reduction in cell growth induced by 100nM Gx15-
070 was calculated from the MTS data in the presence or absence of the indicated inhibitors. 
Value >1 (red): rescue of GX15-070 effect; Value = 1 (white): no effect; Value <1 (green): 
enhanced Gx15-070 effect. (B) Time-course electron microscopic morphology of T1682 cells 
treated with Gx15-070 at the indicated concentrations.  After 1-hour treatment, lamellar 
bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural 
changes with loss of cristae (orange arrow) were evident.  After 6-hour treatment, early signs 
of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss 
of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 
48-hour treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of 
autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of 
autophagic cell death with cytoplasmic vacuolization and lamellar bound structures 
consistent with autophagosomes. (C) GX15-070 (1µM) induced LC3BII accumulation after 
48 hours treatments in thymic epithelial tumor cells (top blot). LC3BII accumulation was 
observed in T1682 cells 1-hour after GX15-070 treatment at a concentration as low as 100nM 
(bottom blot). (D) shRNA knock-down of Beclin1 (sh-BECN1-1 and sh-BECN1-2) and 
RIPK1 (sh-RIPK1-1 and sh-RIPK1-2) in T1682 and TY82 cell lines. Western blot shows 
protein expression in parental cells , cells treated with the target shRNAs , and with a vector 
control (sh-FF2) carrying anti-exogenous luciferase shRNA FF2. MTS results show that 
shRNA knockdown of BECN1 and RIPK1 reduces the effect of Gx15-070 on cell 
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proliferation compared to vector control. * denotes statistically significant differences 
compared to control. 
 
 
Figure 3.23: Percentage of cell death was calculated by LDH release (Cyto Tox assay) after 
48-hour 100nM Gx15-070 treatment for TY82 cell line. Both necroptosis inhibitor NEC1 
(30µM) and autophagy inhibitor CQ (25µM) significantly reduced the amount of cell death 
(One way ANOVA p<0.0001); Dunn post-hoc p value was <0.05 for all cells treated with 
inhibitors plus Gx15-070 compared to cells treated by Gx15-070 alone. 
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4. Discussion and conclusions 
The evaluation of genomic aberrations of TETs revealed CDKN2A as candidate 
prognostic factors and BCL2 antiapoptotic proteins targets suitable for therapy. Firstly, we 
evaluated the expression of BRD4 –NUT fusion gene and the frequency of KIT mutations, 
two known genomic aberrations of TETs: but a remarkably low frequency was estimated for 
these molecular events. Thus, a genome wide approach was adopted starting from whole 
genome sequencing of a B3 thymoma. Whole exome sequencing was adopted to search for 
recurrent mutations in TETs and to expand knowledge learned from whole genome 
sequencing. An heterogeneous pattern of mutations was estimated from exome sequencing 
data, however, recurrent CN loss interesting CDKN2A and CDKN2B loci as well as CN 
gains of BCL2 were identified. Therefore the presence of these genomic aberrations was 
determined in a larger series of FFPE tumors collected retrospectively.  Combining GISTIC 
analysis and patients’ survival data, we established that focal CN gain of BCL2 and CN loss 
of CDKN2A/B loci were the only CN aberrations that significantly correlated with both DRS 
and TTP. Moreover, loss of p16INK4 expression was associated with worse prognosis. Using 
siRNA and small molecule inhibitor approaches, we showed that TET cells underwent 
autophagy-dependent necroptosis after Gx15-070 treatment and that ABT263-sorafenib 
combination inhibited TET cell growth, providing the first preclinical evidence that 
deregulated BCL2 family genes may serve as suitable targets for TET therapies.  
Large arm-level aberrations identified in our study are in general agreement with 
genetic alterations reported by conventional CGH 115,222,223. Only few CN aberrations and 
LOHs have been reported for type A thymomas, which have a very indolent behavior and 
excellent survival 223. B2/B3 thymomas showed frequent arm-level CN gain of 1q and loss of 
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chromosome 6, together with other CN aberrations that are present in less than 20% of the 
cases. B3 thymomas and TCs displayed a pattern of CN aberrations similar to B2/B3 tumors 
except for the losses of 13q, 16q and 17p, which were not observed in B2/B3 tumors. 
Consistent with data from frozen tumors and previous reports 95,222, hierarchical cluster 
analysis of arm-level CN aberrations revealed that type A thymomas were very distantly 
related to aggressive tumors (B3 and C), suggesting that arm-level CN aberrations associates 
with aggressive disease. In addition, loss of 13q, which has been previously described in B3 
and TC by conventional CGH 115, correlated with worse prognosis. RB1, a well-characterized 
tumor suppressor gene, has been mapped to 13q. From the patients evaluated for exome 
sequencing, 29% presented deletion of chromosome 13q: all of them were infiltrating tumors 
(stage IIB-IVB) and classified as aggressive histotypes: 2 thymic carcinomas, 3 B and 2 B2 
thymomas. We found only one TET with concomitant loss of 13q and CDKN2A locus. 
CDKN2A encodes p16INK4 and p14ARF via alterative splicing. As p16INK4, an inhibitor 
of CDK4-cyclin D, acts upstream of RB, inactivation of either gene will be in theory 
sufficient to compromise the RB pathway. The near mutual exclusive loss of 13q and 
CDKN2A which together represented 15% (9/59) of TETs in our series suggests that the RB 
pathway plays an important role in TET pathogenesis.  
Using GISTIC algorithm we identified several cancer related genes involved in cell 
cycle control (CDKN2A/B and CDK4), or intracellular signal transduction (AKT1, PIK3CD 
and HRAS). Interestingly many of these genes (BCL2, BCL-XL, PDCD1, CRK) were related 
to apoptosis control, and BCL2 CN gain correlated with poorer TTP and DRS. CN gain of 
MLC1, another member of the BCL2 family gene, was found in 51% of TETs. This CN gain 
was more frequent in aggressive histotypes (83% B2/B3, 70% B3 and 57%TC). However, 
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MCL1 CN gain was mainly the result of the whole 1q gain rather than focal MCL1 CN 
amplification.  
The oncogenic role of BCL2 is well-known in follicular lymphomas in which 
constitutive BCL2 activation due to IgH-BLC2 juxtaposition is thought to result in 
lymphomagenesis by interfering with the normal apoptosis of B lymphocytes 224. BCL2 
overexpression was observed in other types of lymphoproliferative disorders and small cell 
lung cancer 218. In addition to their involvement in regulation of apoptosis, BCL2 family 
members are also involved in the regulation of autophagy and necroptosis pathways. We 
validated the functional significance of BCL2 family genes in TET cells via siRNA 
approaches, and demonstrated that all TET cell lines (T1889, TY82 and T1682) were 
addicted to BCL2, whereas T1889 and TY82 required MCL1 for growth and survival. More 
importantly, we showed that sorafenib (a multi-tyrosine kinase inhibitor), was capable of 
decreasing MCL1 expression 219 and that ABT263/sorafenib combination was highly 
synergic in inhibiting TET cell proliferation. We also showed that Gx15-070, a pan inhibitor 
of BH3 BCL2 anti-apoptotic family members, potently inhibited TET cell proliferation and 
induced cell death. Interestingly, cell death could be rescued by Beclin1, RIPK1 knockdown 
or by autophagy and necroptosis inhibition, suggesting that Gx15-070-induced a block of cell 
proliferation autophagy-dependent. Taken together, our data strongly indicate that BCL2 
family genes are deregulated in TET cells and potential targets for TET treatment. The effect 
of Gx15-070 was not limited to in-vitro models of TET, indeed a mouse xenograft of TY82 
was established and inhibition of cell proliferation demonstrated. Tumors in the 10 treated 
mice grow slower than those in the 10 untreated animals (Figure 3.19). These data support 
the design of a phase 2 clinical trial of Gx15-070 in TET patients since safety data are already 
available from phase I reports. 
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In conclusion, we identified CN losses of CDKN2A and 13q as poor prognostic 
candidate markers in TETs, implying that RB pathway deregulation may be important in TET 
pathogenesis. Focal BCL2 amplification suggests that this gene is deregulated in TETs and 
Gx15-070 may represent a novel treatment strategy for patients.  
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7. Abbreviations 
TET Thymic epithelial tumors 
WHO World Health Organization 
CN Copy number 
CGH Comparative genomic hybridization 
FISH Fluorescence in situ hybridization 
DN double negative 
DP double positive 
SP single positive 
MEC medulla epithelial cell 
CEC Cortex epithelial cell 
DC dendritic cell 
TCR T cell receptor 
SEER Surveillance, Epidemiology and End Results 
TC thymic carcinoma 
SIR Standardized incidence ratio 
AIDS Acquired immune deficiency syndrome 
EBV Epstein Barr virus 
MEN1 Multiple endocrine neoplasm 
MG Myasthenia gravis  
OS overall survival 
DRS Disease related survival 
TTP Time to progression 
RR Response rate 
CR complete response 
PR partial response 
SD stable disease 
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ACTH Adrenocorticotropic hormone 
IMRT Intensity modulated radiotherapy 
R0 Complete resection 
R1 Microscopically incomplete resection 
R2 Macroscopically incomplete resection 
CI Confidence interval 
GH Growth hormone  
SV40 simian virus 40  
FFPE Formalin fixed paraffin embedded  
BAC Bacterial artificial chromosome 
DAB 3’,3’-diaminobenzidine 
HRP Horseradish peroxidase 
TBS Tris buffered saline  
TBST Tris buffered saline and tween 20 
H&E Haematoxylin & Eosin 
DNBs DNA nano-balls 
SNV single nucleotide variation 
SNP single nucleotide polymorphism  
INDEL insertion/deletion 
OCT optimal cutting temperature 
EDTA Ethylenediaminetetraacetic acid 
GISTIC Genomic Identification of Significant Targets in Cancer 
GATK Genome Analysis Tool Kit 
RIN RNA integrity number 
GA-II Genome analyzer-II 
7AAD 7-amino-actinomycin D 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium assay  
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IHC Immunohistochemistry 
Uk Unknown 
Nr Not reached 
miRNA Micro RNA 
siRNA Small interference RNA 
shRNA Small hairpin RNA 
scRNA Scramble siRNA 
CIx Combination Index 
NEC1 Necrostatin 1 
QC Chloroquine 
FF2 Fire fly luciferase 
 
 
